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7INTRODUCTION
Rodenticide toxicity is one of the common modes of poisoning
encountered in our part of the country.  It is cheap and easily available in
the market, in various forms such as powder, cake, paste etc... The
rodenticides manufactured by standard companies has a fixed
concentration of chemical, whereas the locally made rodenticides do not
have such fixed concentration.
Rodenticide toxicity can range from asymptomatic presentation to
life threatening complications and death, based on the amount and type of
rodenticide ingested.
As compared to older and conventional rodenticides, the newer and
modern rodenticides are more toxic to human beings.
There are case studies and case reports that highlight the toxic
effects of various types of rodenticides in human beings. This study is
about the clinical profile and the outcome of patients with rodenticide
poisoning.
8REVIEW OF LITERATURE
A rodenticide is any commercially available product that is
designed to kill rats, mice, squirrels and other small rodents. Rodenticides
includes various compounds ranging from highly toxic compounds
requiring just a single dose ingestion like zinc phosphide, yellow
phosphorus, sodium monofluroacetate, fluroacetamide, arsenic, thallium
to less toxic compounds requiring repeated ingestion over a period of
time like warfarins, and scilliroside.
Figure - 1 Commercially available Rodenticides
Local made           Company made
Since the rodenticides are agents that are specifically designed to
kill mammals, its toxic effects are very similar both against rodents and
human beings. As the rodents have developed resistance to the existing
rodenticides there is a necessity for development of newer and more toxic
rodenticides. As the rodents are resistant to warfarin baits, the
9development of superwarfarins has posed a higher risk to human beings [1,
2]. Rodenticide toxicity in humans occurs either as a result of accidental
ingestion or as a result of suicidal intent.
Table - 1CLASSIFICATION OF RODENTICIDES
S.NO CLASS EXAMPLE
1 Coumarins First generation : Warfarin, Coumachlor,
Coumafuryl, Coumatetralyl, Dicoumarol
Second generation : Brodifacoum,
Bromadiolone, Difenacoum, Difethialone
Flocoumafen
2 Indandione Chlorophacinone, Diphacinone, Pindone,
Valone
3 Inorganic Zinc phosphide, Arsenous oxide, Yellow
phosphorus, Potassium arsenite, Sodium
arsenite, Thallium sulphate
4 Organochlorides Gamma-HCH, HCH, Lindane
5 Organophosphorus Phosacetim
6 Organofluorides Fluoroacetamide, Sodium fluoroacetate
7 Pyrimidinamine Crimidine
8 Urea Pyrinuron
9 Thiourea Promurit, Thiosemicarbazide
10 Carbanilate 3-Pyridylmethyl 4- nitro carbanilate
11 Botanical Scilliroside, Strychnine
12 Unclassified Bromethalin, Chloralose, tetramine Alpha-
chlorohydrin,  Cholecalciferol,
Flupropadine, Hydrogen cyanide,
Norbormide, Silatrane,
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ANTICOAGULANT RODENTICIDES
Anticoagulant rodenticides mainly comprises of Coumarins (4-
hydroxycoumarin) and 1,3-Indandiones.Warfarin, a 1st generation
coumarin is an active ingredient present in most of the commercially
available rodenticides. Due to their shorter half-life they are required in a
much higher concentration (<0.1%) than 2nd generation coumarins
(0.001% - 0.005%) to exert their desired anticoagulant effect [3].
Figure – 2 Structure of Coumarins and Indandiones
1,3Indandione
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To achieve a particular anticoagulant effect, 1st generation
compounds require multiple dosing when compared to second generation
compounds which require just a single dose. As the second generation
compounds are highly toxic they are commonly referred as “Super
Warfarins” [4]. These compounds are easily absorbed from the
gastrointestinal tract and rarely across the skin.
Bromadiolone and Brodifacoum are commercially available in
cake and powder form. It is commonly available at a concentration of
0.005 % wax cake (Bromadiolone). However locally manufactured
powders do not have a fixed concentration of the active ingredient present
in them.
Figure - 3 Bromadiolone in cake and powder form
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Mechanism of action:
Vitamin K dependent clotting factors (2, 7, 9, and 10) are the main
targets of these anticoagulant rodenticides. These compounds inhibit
vitamin K1 -2,3 epoxide reductase, thereby preventing vitamin K to get
converted to its active state. Warfarin mainly targets prothrombin and
factor X. Hence the measurement of prothrombin time is used to assess
the severity of warfarin toxicity.
Figure – 4 Warfarin - Site of action
The prolonged duration of action of the 2nd generation compounds
(superwarfarins) is due to the following reasons [5]:
1. It has a high affinity for vitamin K1-2,3-epoxide reductase,
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2. It accumulates more in the liver,
3. It targets the Vitamin K – Epoxide cycle at multiple levels, and
4. It has a prolonged half-life.
These agents also increase the capillary permeability and thereby
causing haemorrhage inside our body. Haemorrhage due to warfarin
toxicity occurs few days after poisoning as the clotting factors 2, 7, 9, and
10 have a longer half-life [1, 2]. But the second generation compounds can
cause lethal haemorrhage earlier even with low doses [1].
Figure – 5 Coagulation cascade
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After the ingestion of toxic doses of warfarin or superwarfarin, the
prolongation of prothrombin time can occur within a day, but the time for
maximum prolongation may take upto 3 – 4 days [1, 6, 7]. At low doses, the
only manifestation may be prolonged prothrombin time instead of
haemorrhage.
Toxicity:
The toxic dose for superwarfarins in humans has not been
established. But, as low as 1 milligram of brodifacoum, a second
generation coumarin has produced significant toxicity in adults [1]. Larger
single doses with suicidal intent have resulted in significant symptoms
due to the longer half-life of superwarfarins  [2].
Clinical features:
Haemorrhagic manifestations like epistaxis, gum bleed, upper GI
bleed, subconjunctival haemorrhage and petechiae are commonly seen[1, 2,
8, 10]. In case of severe poisoning, shock and even death can occur.
Some indandiones exhibit  signs of cardiopulmonary and
neurologic insult in rodents causing death before haemorrhage occurs.
Such actions occur only in rodents and have not yet been reported in
human beings.
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Management:
1. Gastric Lavage:
Gastric lavage is done using a nasogastric tube if the patient
presents within 1 hour of ingestion. Lavage performed after one hour of
ingestion has no proven benefits.
2. Activated charcoal:
Activated charcoal effectively absorbs the ingested rodenticide if
given within 1 hour of ingestion [4].  It  is  administered at  a  dose of  25 to
100 grams mixed with 400-800 ml of water.
3. Vitamin K1:
There is a decrease in plasma prothrombin levels within 24-48
hours of poisoning and this may persist for at least one to three weeks.
Due to this reduced plasma prothrombin concentration there is an
increase in prothrombin time [1, 6, 7]. Patients who present earlier after
ingestion (< 24 hrs) will have a normal prothrombin time. But in many
patients who had a normal prothrombin time at 24 hours had a prolonged
prothrombin time at 48 hours [7].
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In cases of accidental ingestions involving a very small amount,
medical management is usually not required, but those patients must be
observed for any bleeding manifestations.
In cases of suicidal ingestion of unknown or relatively large
amounts, phytonadione (vitamin Kl) is administered orally to protect the
patient against the anticoagulant effect of these rodenticides.
Phytonadione administration has no potential adverse effect on the
patient.
Figure –6 Action of Vitamin K1
In cases where larger amount has been ingested, phytonadione
therapy should be started along with monitoring of prothrombin time
serially at 24 and 48 hours. Patients with increased prothrombin time or
bleeding manifestations should be treated only with vitamin K1 and not
with vitamin K3 or vitamin K4. For adults and children over 12 years the
dose of vitamin K1 is fifteen to twenty-five mg.
17
If the prothrombin time is significantly prolonged, phytonadione
should be administered intramuscularly at a dose of 5 – 10 mg. Upto 125
mg of phytonadione may be needed to treat patients with brodifacoum
poisoning who had persistently elevated prothrombin time despite regular
treatment [8, 9, 11]. Phytonadione dose must be repeated if the prothrombin
time has not decreased from the original value since 24 hours.
Patients who had consumed a very large quantity of superwarfarin
compounds will have decreased or low level of prothrombin activity for a
very long period and hence those patients may require treatment for as
long as three to four months [8, 9].
If the patient bleeds as a result of anticoagulant poisoning,
phytonadione must be administered intravenously at a higher dose (10
mg). Phytonadione is diluted in normal saline or dextrose containing
fluids and administered as intravenous infusion. The rate of infusion
should not be too rapid. The response is usually seen within 3-6 hours. In
cases of superwarfarin toxicity subsequent dosages should be adjusted
based on response to therapy [8, 9, 11].
In cases of severe bleeding fresh blood or fresh frozen plasma
should be supplemented along with phytonadione and other supportive
measures. Prothrombin time and haemoglobin levels are checked every
six to twelve hours to monitor the effectiveness of the treatment.
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INORGANIC RODENTICIDES
METAL PHOSPHIDE:
There are different types of metal phosphides used in the
manufacturing of rodenticides. Single dose poisoning can be lethal when
ingested in sufficient amounts.
Table – 2 Physical appearance and lethal dose of various metal
phosphides
METAL
PHOSPHIDE
PHYSICAL
APPEARANCE
LETHAL DOSE
Aluminium Yellow or dark grey crystals 20 mg/kg
Zinc Grey tetragonal crystals/grey
black powder
4–5 g (Toxic
dose)
Magnesium Yellow-green crystals 10.4 mg/kg
Calcium Red-brown crystals/grey
lumps
8.7 mg/kg
Of the above mentioned metal phosphides, only zinc phosphide is
used in baits. Other phosphides are used as fumigant rodenticide.
19
Zinc phosphide is a grey-black coloured compound available in
powdered form. It has garlic like odour [12]. Its toxicity is primarily due to
its hydrolysed product called phosphine, a colourless and flammable gas
[12, 13, 14].
Figure – 7 Commercially available zinc phosphide powder
Zinc phosphide is used as baits at a concentration of 0.75 – 2 %.  In
the rodenticide formulation along with 75 % of zinc phosphide, 25 % of
antimony potassium tartrate is added as an emetic. This is added to
induce vomiting if it is accidentally ingested by human beings.
Zinc phosphide requires acidic PH to get hydrolysed and liberate
phosphine, whereas other metal phosphides hydrolyse at a neutral pH [15].
20
The toxic dose of aluminium phosphide for humans is considered
to be 150 – 500 mg. Serum phosphine levels of more than 1.6 milligram /
dl are considered to have a high mortality rate.
Mechanism of action:
The exact mechanism of action is not clear but the following
mechanisms have been hypothesized
1. It inhibits Cytochrome C oxidase
2. It inhibits oxidative respiration
3. It blocks the protein and enzyme synthesis[16]and thereby blocks
mitochondrial respiration
4. It produces of free radicals that inhibits the catalase and peroxidase
and also causes lipid peroxidation
5. It has a corrosive effect on the exposed tissues
6. Toxicity due to zinc, magnesium or aluminium [17, 18, 19]
7. Phosphine also exerts an anticholinesterase activity [18]
8. Impairment of glycogenolysis and gluconeogenesis[20, 21]
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Clinical features:
Zinc phosphide is much less corrosive to skin and mucous
membranes, but on inhalation it can cause pulmonary oedema. The
emetic effect of zinc and antimony potassium tartrate may provide
protection; however, patients develop excitement, chills, chest tightness,
breathlessness and even pulmonary oedema.
At toxic dose it can cause hepatic failure, renal failure, tetany, and
arrhythmias which can be fatal [21, 22].
TREATMENT
The treatment of metal phosphide poisoning is mainly supportive.
Securing of airway and controlling the seizures (if present) should be
given priority over gastrointestinal decontamination.
Metal phosphides react with the acidic contents in the stomach and
liberate phosphine gas. This toxic gas is present in the vomitus, lavage
fluid, and the faeces of the patient and hence care should be taken to
avoid inhalation of the toxic gas.
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Test for phosphine gas [23]:
The gastric lavage fluid (5 ml) is diluted with 15 ml of water and
heated in a container for fifteen to twenty minutes at 50 degree Celsius.
The mouth of the container should have two filter papers coated with 0.1
N silver nitrate and 0.1 N lead acetate.
If phosphine gas is present, it will turn the silver nitrate paper black
due to the formation of metallic silver and the other paper will not have a
change in colour. If both the papers turn black, it signifies the presence of
hydrogen sulphide.
1. GASTRIC LAVAGE:
Gastrointestinal decontamination is effective in the patients who
present to the hospital within 1 hour of ingestion. Lavage performed after
1 hour of ingestion has no proven benefits.
2. SUPPORTIVE MANAGEMENT:
Vital signs must be monitored periodically. Blood sugar,
electrolytes and pH are constantly monitored and treated accordingly with
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appropriate IV fluids. Patients can develop acidosis, which should be
treated promptly by appropriate IV fluids.
3. OXYGEN:
Low concentration oxygen is given by nasal mask. Pulmonary
oedema is managed with intermittent or continuous positive pressure
ventilation. Oxygen should not be used at a higher concentration for
prolonged periods, because it may add on to the lung injury.
4. MAGNESIUM SULPHATE:
Patients with zinc or aluminium phosphide toxicity, when treated
with magnesium sulphate have lesser complications and more favourable
outcome [21, 22, 25]. Although the exact mechanism is not clearly
understood, it may be due to the special property that magnesium
stabilizes the cell membrane and prevents the occurrence of life
threatening arrhythmias.
Moreover intracellular magnesium is used as a cofactor in the
synthesis of glutathione and other antioxidants [26]. Hence intravenous
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magnesium sulphate may be used in the setting of acute metal phosphide
poisoning.
Dose of magnesium sulphate
Three grams IV infusion is given over a period of 3 hours,
followed by six grams per day for the next three to five days [22].
Extracorporeal haemodialysis is done if acute kidney injury occurs.
Serum ALP, LDH, Transaminases, prothrombin time, and bilirubin
are monitored for hepatic involvement. Vitamin K1 is given if
prothrombin level declines.
N – Acetyl cysteine [27] and coconut oil has been used with some
success in the treatment of metal phosphide poisoning [28].
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The following protocol can be used in the emergency management
of phosphine or metal phosphide poisoning [29].
Figure – 8 Protocol for management of Metal phosphide poisoning
Accidental / intentional ingestion
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YELLOW PHOSPHORUS
Yellow phosphorus is a highly toxic inorganic element that is
commonly used in crackers, ammunition, fertilizers and rodenticide. It
has a garlic like odour [30] and also called as “White Phosphorus”
As there is an emerging resistance to conventional rodenticides,
yellow phosphorus is now being used as rodenticide in form of a paste.
Since it comes in a paste formulation there is an increased chance of
accidental poisoning particularly among the children [31].
Figure – 9 Commercially available yellow phosphorus
TOXICITY:
Intoxication occurs with suicidal or accidental ingestion. It is easily
absorbed from the gastrointestinal tract and from other mucosal surfaces
and even through skin [30]. It is evenly distributed and concentrated in
many tissues in our body, particularly the liver [32, 33] and the peak level is
reached after 2 to 3 hours of ingestion.  The toxic dose is found to be 15
27
mg and more than 50 mg is considered as a fatal dose (1 mg / kg on the
average) [34].
MECHANISM OF ACTION:
It is a protoplasmic toxin causing multiorgan failure particularly
cardiac,  hepatic,  renal  toxicity.  Its  toxic  effect  is  mainly  due  to  the
alterations that occur in the ribosomal function leading to altered protein
synthesis [35]. It also causes dysregulation of blood sugar & glycogen
deposits [36].
It also affects the lipoprotein synthesis & secretion of tri-
glycerides, causing fatty degeneration of multiple organs [34, 37, 38].
CLINICAL FEATURES:
 Patients with yellow phosphorus intoxication pass through 3
stages.
Table – 3 Stages of Yellow Phosphorus poisoning
S.no Stage Time since poisoning
1 Stage of General symptoms 0 – 24 hours
2 Asymptomatic stage 24 – 72 hours
3 Advanced stage > 72 hours
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Stage of general symptoms:
This stage is predominantly characterised by gastrointestinal
symptoms
1. Abdominal pain,
2.  Nausea & vomiting,
3.  loose stools and
4.  Fever.
Apart from these clinical symptoms, the patients do not have any
abnormalities that can be detected by means of lab investigations.
Asymptomatic stage:
The patient seems to be well preserved and has no symptoms
during this stage. But there will a mild elevation of bilirubin, hepatic
transaminase (SGOT, SGPT) with demonstrable histological changes
suggestive of toxic hepatitis. This is a stage where the patient may be
discharged from the hospital as the patient is symptom free.
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Advanced stage:
This stage occurs after 3 days of poisoning and lasts until recovery
or death of the patient [34, 36, 37, 39, 40].
Table –4 Clinical features in Advanced stage
S.no System Clinical features
1 Cardiovascular
Hypotension, Tachycardia, Arrhythmias,
Cardiogenic shock
2 Gastrointestinal
Acute fulminant hepatitis, Hepatic
encephalopathy, Coagulopathy. (liver
histology shows steatohepatitis and necrosis)
3
Central
nervous system
Irritability, Confusion, Hallucinations,
Psychosis, Coma
4 Renal Acute tubular necrosis, Anuric renal failure
Depending on the amount of yellow phosphorus ingested, some
patients recover from the initial phase of insult spontaneously. The reason
for spontaneous recovery is unknown [35]. Some patients develop oliguria
and acute tubular necrosis and eventually land up in renal failure.
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MANAGEMENT:
1. SKIN DECONTAMINATION As yellow phosphorus can be
absorbed across the skin; all the particles must be cleanly washed
off with water.
2. SUPPORTIVE MANAGEMENT: Airway securing and seizure
control must be done prior to gastric lavage and catharsis.
3. GASTRIC LAVAGE AND CATHARSIS: Gastric lavage with
0.01-0.1% KMO4  (potassium permanganate) or  0.2-0.4%
CuSO4(copper sulphate) solution is done to convert the phosphorus
to relatively harmless oxides which should then be followed by
administration of  activated charcoal adsorbent and 30 minutes
later by a saline cathartic.
Fat favours additional absorption of phosphorus, hence patients
must avoid fat in diet for 3-4 days or longer. Mineral oil dissolves
phosphorus and prevents its absorption and hence it can be taken orally
[41]. It is usually given at a dose of 1.5 ml per Kg body weight. There is no
specific antidote for yellow phosphorus.
Close monitoring of hepatic and renal function must be done and
managed accordingly. Liver transplantation has been successfully done in
suitable candidates for acute hepatic failure [42].
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Yellow phosphorus ingestion carries a grave prognosis unless
treatment is started early. Fernandez and Canizares in a case series of 15
patients have reported a mortality rate of 27%, confirming that yellow
phosphorus is extremely lethal when ingested [40].The mortality rate may
even be as high as 50% [1].
Liver transplantation should be considered in suitable patients.
Patients for liver transplantation are selected as per “Criteria of King's
College, London”.
Table-- 5Criteria for Liver Transplantation in Acute Liver Failure
Criteria of King's College, London
 Acetaminophen cases
Arterial pH <7.3, or
INR >6.5 and serum creatinine >3.4 mg/dL
 Non-acetaminophen cases
 INR >6.5, or
 Any three of the following:
 Age <10 years or >40 years
 Duration of jaundice before encephalopathy >7 days
 Etiology: non-A, non-B hepatitis; halothane hepatitis;
idiosyncratic drug reaction; indeterminate
 Serum bilirubin >17.6 mg/dL
 INR >3.5 (PT >50 seconds)
32
THALLIUM SULPHATE
Besides used in the treatment of TB, syphilis and gonorrhoea in the
past, it was also used as a rodenticide. But now, it is banned in US
because of many human deaths due to poisoning [43]. Because it is
odourless and tasteless it is still being used as a rodenticide and ant killer
in many developing countries.
Thallium sulphate is readily absorbed from the gastrointestinal
system and across the skin.  It  has a high volume of distribution (3.6-5.6
L/kg). Most intravascular thallium is present in RBC. Half-life in humans
is about 1.9 days. Its LD50 in humans is 10 - 15 mg/kg. [44].
MECHANISM OF ACTION
Table – 6 Mechanism of action of Thallium [45]
1 Ribosomal inhibition
2 Disruption of potassium-dependent processes
3 Riboflavin sequestration
4 Interference with the cysteine residues
5 Injury to the Myelin sheath
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TOXICITY
Its lethal dose is considered to be fifteen to twenty mg per kg body
weight. But even lesser doses have caused death. It has a varied clinical
manifestations due to its 3-phase toxicokinetics.
Table - 7 Three phase toxicokinetics
Phase 1
Intravascular
distribution
< 4 hours
 Distributed to organs having
high perfusion (kidney, liver,
muscle)
Phase 2
CNS
distribution
 4-48 hours Distribution into the CNS
Phase 3  Elimination > 24 hours Elimination process starts
Thallium is excreted mainly through faeces (51.4%) and urine
(26.4%).Because of prolonged elimination half-life of 3-30 days; it also
acts as a cumulative poison.
The best method for diagnosis is estimation of twenty four hours
urinary thallium excretion, which is normally less than 10 mcg/L. Values
more than this are corroborative with thallium poisoning [44, 46].
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CLINICAL FEATURES
Early symptoms that occur after acute toxicity are predominantly
gastrointestinal symptoms like
Abdominal pain,
Nausea & vomiting,
Loose stools,
Stomatitis,
Increased salivation,
Ileus.
Hepatic involvement is evidenced by increased transaminases.
Other symptoms which can occur late are headache, muscle weakness,
lethargy, paresthesias, tremor, ataxia and ptosis [44, 47].
Myoclonic movements, convulsions, delirium, and coma occur in
case of severe poisoning. Fever is considered as a poor prognostic sign of
CNS involvement. Alopecia can occur after two weeks or more and is
therefore not helpful in diagnosing at an earlier stage [44, 48].
Cardiovascular effects include early hypotension, due to toxic
cardiomyopathy. Ventricular arrhythmias can occur. Hypertension can
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occur as a late manifestation due to vasoconstriction. It can also lead to
Acute Respiratory Distress Syndrome [49].
Death occurs primarily due to respiratory paralysis or
cardiovascular collapse.
TREATMENT
1. Gastric Lavage:
Gastrointestinal decontamination is effective in patients if done
within one hour of ingestion. Lavage performed after one hour of
ingestion has no proven benefits.
2. Activated charcoal:
Activated charcoal effectively absorbs the thallium if given within
one hour of ingestion [8].  It is administered at a dose of 25 to 100 grams
mixed with 400-800 ml of water. Multiple doses of activated charcoal can
increase the elimination thallium [46].
3. Supportive management:
Electrolyte and dextrose should be administered by IV infusion to
increase diuresis, thereby enhancing urinary excretion of thallium.
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Patients must be carefully monitored for development of
arrhythmias.
4. Haemodialysis and haemoperfusion:
It has been effective in patients with severe poisoning by
decreasing the total body content of thallium.
5. Potassium ferric ferrocyanide:
Also known as Prussian blue, it increases thallium excretion via
faeces.
STRYCHNINE
It is a naturally occurring alkaloid commonly known as nux
vomica. It is rarely used in the manufacture of rodenticides.
MECHANISM OF ACTION
It selectively blocks the post synaptic inhibitive neurons and
thereby causing an excitatory state among the cells of central nervous
system, mainly the spinal cord and medulla. Respiratory arrest either
primarily or secondary to convulsion is the common mode of death.
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Strychnine is rapidly absorbed from the gastrointestinal system. It
is rapidly cleared off the blood stream due its low plasma protein binding
property. It is metabolised by the liver and excreted by the kidneys.
Lethal dose of strychnine is found to be fifty to hundred mg [50].
TREATMENT
1. Early gastrointestinal decontamination with activated charcoal and
potassium permanganate.
2. There is no specific antidote for strychnine poisoning.
3. Anticonvulsants are used for controlling seizures.
4. Acidification of urine can be done to increase the urinary excretion
of strychnine.
CRIMIDINE
It is a synthetic rodenticide [2-chloro-4-(dimethylamino)-6-
methylpyrimidine]. It is a highly toxic compound with a lethal dose of 5
mg/kg. Within thirty minutes of ingestion the physical signs and
symptoms starts to appear.
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Clinical features include restlessness, involuntary movements,
seizures, muscle spasm. If respiratory muscles are involved, patient will
develop respiratory arrest, cyanosis and eventually death [51].
TREATMENT
1. Seizure control with anticonvulsants. Along with anticonvulsants,
pyridoxine can also be used to control seizures.
2. Early gastric lavage with activated charcoal.
3. Administration of sodium bicarbonate along with IV fluids to
enhance excretion of absorbed toxin and to combat metabolic
acidosis that can occur as a result of convulsions.
SODIUM FLUOROACETATE AND FLUOROACETAMIDE
It is easily absorbed from the gastrointestinal system,
Mechanism of action
In the liver it is converted into flurocitrate which is a potent
inhibitor of tricarboxylic acid cycle and thereby inhibiting the cellular
inhibition
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Toxic features
The organs most commonly affected are the heart, brain, and the
kidneys which are manifested as arrhythmias, convulsions [52], metabolic
acidosis and electrolyte imbalance.
TREATMENT:
1. Gastric lavage:
It is effective only when it is done within one hour of poisoning.
However if the patient is having active seizure, it must be controlled first.
2. Seizure control:
For organochloride compounds, diazepam is still preferred over
lorazepam as there is no strong evidence reported in the literature. It is
always advisable to secure the airway and start on mechanical ventilation
to prevent aspiration and related complications.
3. Hypocalcaemia:
For hypocalcaemia10% calcium gluconate solution is given as IV
at a dose of 10 ml (100 mg/ml). ECG must be monitored for arrhythmias
and, if present, it should be treated with appropriate antiarrhythmic drug
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SCILLIROSIDE
It is a naturally available compound that is used in manufacturing
botanical rodenticides.  It is poorly absorbed across the gastrointestinal
tract. This is usually less toxic to humans when compared to other
rodenticides.
MECHANISM OF ACTION
Its toxic properties are mainly due to cardiac glycosides. It
produces alteration in the conduction properties of heart and may produce
arrhythmias.
TREATMENT
Scilliroside is less likely to cause toxicity unless it is consumed at
large dosage because of its intense emetic effect. Only supportive and
symptomatic treatment is given. It includes
1. Gastrointestinal decontamination,
2. Activated charcoal,
3. Cardiac monitoring,
4. Other supportive measures.
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CHOLECALCIFEROL
Cholecalciferol (vitamin D3) exerts its toxic effects due to
hypercalcemia. Cholecalciferol intoxication produces an elevated serum
level of calcium, chiefly the unbound fraction.
Clinical features
Signs and symptoms of hypercalcemia are fatigue, weakness,
headache, and nausea. Features that suggest renal involvement include
polyuria, polydipsia, proteinuria, and azotemia.
TREATMENT
Treatment of cholecalciferol toxicity is mainly focussed on
1. To limit  gastrointestinal absorption,
2. Enhance excretion,
3. To counteract the hypercalcemic effect.
1. Gastric Lavage:
Gastric is usually effective when done within one hour of
poisoning. Lavage performed after 1 hour of ingestion has no proven
benefits.
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2. Activated charcoal:
Activated charcoal is given at a dose of 25-100 g in 300-800 mL
repeated two to four hours.
3. IV fluids
Normal saline or dextrose solutions are used to enhance its
excretion. Blood calcium levels should be constantly monitored.
Urinalysis is done to assess the extent of renal injury.
4. Furosemide
20-40 mg IV or 40-120 mg orally shall be used to enhance diuresis.
5. Predinisone and other glucocorticoids are used to decrease the
elevated blood calcium levels at a dose of one mg per kg per day.
6. Calcitonin can be used at a dose of 4 IU/ Kg twelfth hourly for
two to five days.
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AIMS AND OBJECTIVES
1. To study the clinical profile of patients admitted with rodenticide
poisoning at IMCU, Govt. Stanley hospital, Chennai.
2. To assess the morbidity, mortality and clinical outcome of those
patients.
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MATERIALS AND METHODS
PLACE OF STUDY:
This study has been carried out at the toxicology unit of Intensive
Medical Care Unit and Medical wards of Govt. Stanley hospital, Chennai.
STUDY PERIOD:
One year (From November 2011 to November 2012).
STUDY DESIGN:
This is a Retrospective and Prospective observational study.
ETHICAL COMMITTEE APPROVAL:
The ethical committee approval was obtained for this study.
INCLUSION CRITERIA:
1. Any patient admitted with rodenticide intake.
2. Age of the patients  > 13 years
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EXCLUSION CRITERIA:
1. Mixed poisons,
2. Chronic liver disease,
3. Alcohol intake within 24 hours before admission
4. Patients on drugs like anticoagulants, antiplatelets,
5. Patients with bleeding disorders,
6. Acute diarrhoeal disease,
7. Patients with known coronary artery disease
CONSENT:
The study group thus identified by the above criteria (inclusion and
exclusion criteria) was first instructed about the nature of the study.
Willing participants were taken up for this study after getting a written /
informed consent from these patients or their relatives in the local
vernacular language.
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STUDY SUBJECTS:
All the patients who fulfilled the inclusion criteria above 13 years
of age and both genders were included in this study. The included
patients were subjected to detailed history taking, complete physical
examination and the relevant laboratory investigations.
The details of the type and the amount of rodenticide ingested were
collected from the patients or their relatives.
DEFINITIONS AND REFERENCE LAB VALUES USED IN THE
PRESENT STUDY:
Acute hepatitis[53]: Acute onset of inflammation of liver which is
evident clinically as low-grade fever, anorexia, nausea, vomiting, fatigue,
malaise, dark urine, jaundice, hepatomegaly with or without
splenomegaly or lymphadenopathy. It is diagnosed by either an increase
in serum bilirubin along with elevated transaminases (SGOT & SGPT) or
by means of liver biopsy.
Acute liver failure [53]: Acute liver failure (or fulminant hepatic
failure) originally was defined by an interval of eight weeks or less
between the onset of illness and appearance of encephalopathy
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Hepatic encephalopathy[53]: Reversible neurologic and psychiatric
manifestations usually found in patients with chronic liver disease and
portal hypertension, but also seen in patients with acute liver failure.
Myocarditis: Signs of myocardial inflammation evidenced by
echocardiogram and elevated cardiac enzymes (Troponin I and T).
ARDS (Acute respiratory distress syndrome)[54]: It is a clinical
syndrome of sudden onset severe dyspnoea, hypoxemia, and diffuse
pulmonary infiltrates leading to respiratory failure. It is diagnosed by
arterial PaO2/FIO2 > 200 mmHg, presence of bilateral alveolar or
interstitial infiltrates in chest X – ray and PCWP less than 18 mmHg or
no clinical evidence of increased left atrial pressure
AKI (Acute Kidney Injury)[54]: An increase in the blood urea
nitrogen concentration and/or an increase in the plasma or serum
creatinine  concentration, often associated with a reduction in urine
volume.
Hypoglycaemia [54]:  Glucose levels <55 mg/dl
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RFT
Blood sugar – 90-140 mg/dl
Urea – 20-40 mg/dl
Serum Creatinine - 0.5–1.2 mg/dl(males), 0.4 – 1.1 mg/dl (females)
Sodium – 135 – 145 mEq/l
Potassium – 3.5 – 5.1 mEq/l
Bicarbonate – 22- 28 mEq/l
Chloride – 98 - 108 mEq/l
LFT[53]: Serum Total bilirubin - 1.0 and 1.5 mg/dl
Serum indirect bilirubin - 0.8 and 1.2 mg/dl
Serum Transaminase<30 U/L for men and <19 U/L for women.
Bleeding time (BT): 3 – 11 minutes
Clotting time (CT): 4-10 mins
Prothrombin time (PT)11 – 13 seconds
International normalized ratio (INR) 0.8 – 1.1
Activated Partial thromboplastin time (aPTT) 30 – 40 seconds
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LIMITATIONS OF THE STUDY:
1. Long term toxic effects of the rodenticide ingested are not included
in the study.
2. Locally made rodenticide preparations don’t have standard
concentration of active ingredients and hence the outcome in such
patients could not be correlated to the amount of rodenticide
ingested.
3. Quantification of amount ingested is done approximately according
to the patients and their relatives’ history.
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RESULTS AND OBSERVATION
The total number of patients included in the study was 421. But
only 303 patient’s data was finally included for the analysis. The
remaining 118 patients did not give consent, absconded or were
discharged prematurely before the completion of investigations and were
excluded from the study. The remaining 303 patients’ data were taken for
final analysis.
AGE AND SEX DISTRIBUTION
Table - 8 Age distribution
Age group (years) No.of patients %
14 - 20 93 30.7 %
21 – 30 150 49.5 %
31 – 40 44 14.5 %
41 – 50 8 2.6 %
>50 8 2.6 %
Total 303 100 %
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Out of 303 patients studied most of the patients were below 30
years of age. 93 (30.7%) patients were between 14-20 years, 150 (49.5%)
patients were between 21-30 years, 44(14.5%) patients were between 31-
40 years, 8 (2.6%) were between 41-50 years, 8(2.6 %) patients were
more than years of age.
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Figure - 10 Age distribution
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SEX AND MARITAL STATUS DISTRIBUTION
Table –9 Sex and Marital status distribution
Gender
Married Unmarried No. of patients
N % N % N %
Male 96 56.8 73 43.2 169 100
Female 82 61.2 52 38.8 134 100
Total 178 58.7 125 41.3 303 100
Out of the 303 patients studied178 (58.7%) were married and 125
(41.3%) were unmarried. 169(55.8 %) were males and 134 (44.2 %) were
females. Out of 169 males 96 (56.8%) were married and 73 (43.2%) were
unmarried. Out of 134 females 82 (61.2%) were married and 52 (38.8%)
were unmarried.
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MODE OF POISONING
Table –10 Mode of poisoning
Mode of poisoning No.of patients %
Suicidal 300 99.0 %
Accidental 3 1.0 %
Total 303 100 %
Out of the 303 patients studied, 300 (99%) patients consumed
rodenticide for committing suicide, 3 (1%) patients consumed rodenticide
accidentally.
Suicidal
99%
Accidental
1%
Figure 12- Mode of poisoning
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POISONING TO HOSPITAL PRESENTATION - TIME INTERVAL
Table –11 Time delay to present to hospital
Poisoning to hospital presentation -
Time interval
No. of patients %
0 - 2 hours 112 37.0 %
2 – 6 hours 163 53.8%
6 – 12 hours 19 6.2%
12 – 24 hours 3 1.0%
> 24 hours 6 2%
Total 303 100%
Out of the 303 patients studied 112 (37%) patients reached the
hospital within 2 hours of consumption of rodenticide, 163 (53.8%)
patients reached at 2 – 6 hours, 19(6.3%) patients reached at 6 – 12 hours,
3 (1%) patients reached at 12 – 24 hours, and 6 (2%) patients took more
than 24 hours to reach the hospital.
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Figure - 13 Time delay to present to hospital
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TYPE OF RODENTICIDE CONSUMED
Table –12 Type of Rodenticide consumed
Rodenticide type No. of patients %
Zinc phosphide 169 55.8%
Bromadiolone 119 39.3%
Brodifacoum 7 2.3%
Yellow phosphorus 8 2.6%
Total 303 100%
Out of the 303 patients studied 169 (55.8 %) consumed Zinc
phosphide, 119 (39.3%) consumed Bromadiolone, 7 (2.3%) consumed
Brodifacoum, 8 (2.6 %) consumed yellow phosphorus.
Zinc phosphide
169
Bromodialone
119
Brodifacoum
7
Yellow
phosphorus 8
Figure - 14 Type of Rodenticide consumed
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CLINICAL FEATURES AT PRESENTATION - ZINC PHOSPHIDE
Table –13 Clinical features of Zinc phosphide poisoning
Clinical feature No. of patients %
Vomiting 143 84.6%
Abdominal pain 47 27.8%
Icterus 3 1.8%
None 17 10.1 %
Total 169 100 %
Out of 169 patients who consumed zinc phosphide, 143 (84.6%)
patients had vomiting, 47 (27.8%) had abdominal pain and 3 (1.8%)
patients had icterus at presentation. Some of the patients had combination
of these symptoms. 17(10.1%) patients had no complaints at presentation.
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Figure - 15 Clinical features of Zinc phosphide
poisoning
57
CLINICAL FEATURES AT PRESENTATION - BROMADIOLONE
Table –14 Clinical features of Bromadiolone poisoning
Clinical Features No. of patients %
Vomiting 38 31.9%
Abdominal pain 16 13.4%
None 76 63.9%
Total 119 100%
Out of 119 patients who consumed bromadiolone 38 (31.9%)
patients had vomiting, 16 (13.4%) patients had abdominal pain and 76
(63.9%) had no complaints at presentation. Some of the patients had
combination of these symptoms.
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Figure - 16 Clinical features of Bromadiolone poisoning
58
CLINICAL FEATURES AT PRESENTATION - BRODIFACOUM
Table –15 Clinical features of Brodifacoum poisoning
Clinical feature N %
 Vomiting 5 71.4%
Abdominal pain 3 42.9%
None 2 28.6%
Total 7 100%
Out of 7 patients who consumed brodifacoum 5 (71.4%) had vomiting
and 3 (42.9%) had abdominal pain. Some of the patients had combination
of these symptoms. 2 (28.6%) patients had no complaints at presentation.
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Figure - 17 Clinical features of Brodifacoum poisoning
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CLINICAL FEATURES AT PRESENTATION - YELLOW
PHOSPHORUS
Table –16 Clinical features of Yellow phosphorus poisoning
Clinical feature No. of patients %
Vomiting 6 75%
Abdominal pain 6 75%
Haemetemesis /
malena
3 37.5%
Icterus 6 75%
Total 8 100%
Out of the 8 patients who consumed yellow phosphorus, 6 (75%)
patients had vomiting, 6 (75%) patients had abdominal pain, 3 (37.5%)
patients had haemetemesis / malena, and 6 (75%) patients had icterus at
presentation.
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Figure - 18 Clinical features of Yellow phosphorus
poisoning
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VITAL SIGNS AT PRESENTATION
    Table –17 Blood Pressure  Table –18 Pulse rate
BP
No.of
patients
% Pulse rate
No.of
patients
%
Normotension 302 99.7% Normal 296 97.7%
Hypotension 1 0.3% Bradycardia 0 0%
Hypertension 0 0% Tachycardia 7 2.3%
Total 303 100% Total 303 100%
Out of the 303 patients studied 302 (99.7%) patients had normal
BP and 1 (0.3%) patient had hypotension and none had hypertension. Out
of the 303 patients studied 296 (97.7%) had normal pulse rate, 7 (2.3%)
had tachycardia and none had bradycardia.
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BLOOD SUGAR AT ADMISSION
Table -19 Blood sugar at admission
Rodenticide type
>90mg% 55 – 90mg% < 55mg% Total
N % N % N % N %
Zinc Phosphide 93 55.0 67 39.6 9 5.3 169 100.0
Bromadiolone 110 92.4 9 7.6 0 0.0 119 100.0
Brodifacoum 6 85.7 1 14.3 0 0.0 7 100.0
Yellow Phosphorus 7 87.5 1 12.5 0 0.0 8 100.0
Total 216 71.3 78 25.7 9 3.0 303 100.0
Out of 169 patients who consumed zinc phosphide 93 (55%)
patients had blood sugar > 90mg /dl, 67 (39.6%) patients had blood sugar
of 55 – 90 mg /dl, and 9 (5.3%) patients had blood sugar less than 55mg /
dl.
Out of 119 patients who consumed bromadiolone 110 (92.4%)
patients had blood sugar > 90mg / dl, 9 (7.6%) patients had blood sugar
of  55  –  90  mg  /  dl,  and  none  of  the  patients  had  blood  sugar  less  than
55mg / dl.
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Out of 7 patients who consumed brodifacoum 6 (85.7 %) patients
had blood sugar > 90mg / dl, 1 (14.3%) patient had blood sugar of 55 –
90 mg / dl, and none of the patients had blood sugar less than 55mg / dl.
Out of 8 patients who consumed yellow phosphorus, 7 (87.5%)
patients had blood sugar > 90mg / dl, 1 (12.5%) patient had blood sugar
of 55 – 90 mg / dl, and none of the patients had blood sugar less than 55
mg / dl.
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Figure - 20 Blood sugar at admission
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INR - 48 HOURS AFTER ADMISSION
Table –20 INR - 48 hours after admission
INR at 48 hours after admission
Total
<1.1 1.1 - 2 2.1 – 3 3.1 - 4 >4
N % N % N % N % N % N %
Zinc Phosphide 163 96.4 4 2.4 0 0.0 0 0.0 2 1.2 169 100.0
Bromadiolone 48 40.3 7 5.9 35 29.4 23 19.3 6 5.0 119 100.0
Brodifacoum 2 28.6 0 0.0 4 57.1 1 14.3 0 0.0 7 100.0
Yellow
Phosphorus 0 0.0 4 50.0 2 25.0 2 25.0 0 0.0 8 100.0
Total 213 70.3 15 5.0 41 13.5 26 8.6 8 2.6 303 100.0
Out of 169 patients who consumed zinc phosphide 163 (96.4%)
patients had an INR <1.1, 4 (2.4%) patients had an INR 1.1 - 2, and2
(1.2%) patients had an INR >4.Out of 8 patients who consumed yellow
phosphorus, 4 (50%) patients had an INR 1.1 - 2, 2 (25%) patients had an
INR 2.1 – 3, and 4 (50%) patients had an INR 3.1 – 4.
Out of 119 patients who consumed bromadiolone 48 (40.3%)
patients had an INR <1.1, 7 (5.9%) patients had an INR 1.1 - 2, 35
(29.4%) patients had an INR 2.1 – 3, 23 (19.3%) patients had an INR 3.1
– 4, and 6 (5%) patients had an INR >4.
Out of 7 patients who consumed brodifacoum 2 (28.6%) patients
had an INR <1.1, 4 (57.1%) patients had an INR 2.1 – 3, 1 (14.3%)
patient had an INR 3.1 – 4.
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LIVER FUNCTION TEST
Table –21 Liver Function Test
Rodenticide type
Normal LFT Abnormal LFT Total
N % N % N %
Zinc Phosphide 164 97.0 5 3.0 169 100%
Bromadiolone 119 100.0 0 0.0 119 100%
Brodifacoum 7 100.0 0 0.0 7 100%
Yellow Phosphorus 0 0.0 8 100.0 8 100%
Total 290 95.7 13 4.3 303 100%
Out of 169 patients who consumed zinc phosphide 164 (97%)
patients had normal LFT, and 5 (3%) patients had abnormal LFT.
Out of 119 patients who consumed bromadiolone, all 119 (100%)
patients had normal LFT and none of the patients had abnormal LFT.
Out of 7 patients who consumed brodifacoum, all 7 (100%)
patients had normal LFT, and none of the patients had abnormal LFT.
Out of 8 patients who consumed yellow phosphorus, all 8 (100%)
patients had abnormal LFT and none of the patients had normal LFT.
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COMPLICATIONS OF ZINC PHOSPHIDE POISONING
Table -24 Complications of Zinc phosphide poisoning
Complication No. %
None 154 91.1 %
?INR without haemorrhage 4 2.3 %
?INR with haemorrhage 2 1.18 %
Acute hepatitis 5 2.95 %
Hepatic encephalopathy 2 1.18 %
Arrhythmia 1 0.6 %
Hypoglycaemia 9 5.3%
Total 169 100%
Out of the 169 patients who consumed zinc phosphide, 4 (2.3%)
patients had increased INR without any haemorrhagic manifestation, 2
(1.18%) patients had increased INR with haemorrhagic manifestation, 5
(2.95%) patients had acute hepatitis, 2 (1.18%) patients had hepatic
encephalopathy, 1 (0.6%) patient had arrhythmia, and 9 (5.3%) patients
had hypoglycaemia.
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Figure - 21 Complications of Zinc phosphide poisoning
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COMPLICATIONS OF BROMADIOLONE POISONING
Table - 23Complications of Bromadiolone poisoning
Complications No %
None 49 41.2 %
?INR without haemorrhage 65 54.6 %
?INR with haemorrhage 5 4.2 %
Total 119 100 %
Out of the 169 patients who consumed bromadiolone, 65 (54.6%)
patients had increased INR without any haemorrhagic manifestation, 5
(4.2%) patients had increased INR with haemorrhagic manifestation, and
49 (41.2 %) patients did not develop any complications.
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Figure - 22 Complications of  Bromadiolone poisoning
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COMPLICATIONS OF BRODIFACOUM POISONING
Table –24 Complications of Brodifacoum poisoning
Complications No %
None 2 28.6 %
?INR without haemorrhage 5 71.4 %
Total 7 100 %
Out of the 7 patients who consumed brodifacoum, 5 (71.4%)
patients had increased INR without any haemorrhagic manifestation, and
2 (28.6 %) patients did not develop any complications.
2
5
0
1
2
3
4
5
6
None ?INR without haemorrhage
Figure - 23 Complications of Brodifacoum poisoning
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COMPLICATIONS OF YELLOW PHOSPHORUS POISONING
Table –25 Complications of Yellow phosphorus poisoning
Complications
No. of
patients %
?INR without haemorrhage 3 37.5
?INR with haemorrhage 5 62.5
Acute hepatitis 8 100
Hepatic encephalopathy 4 50
Myocarditis 1 12.5
AKI 2 25
ARDS 1 12.5
Total 8 100
Out of the 8 patients who consumed Yellow phosphorus, 3 (37.5%)
patients had increased INR without any haemorrhagic manifestation, 5
(62.5%) patients had increased INR with haemorrhagic manifestation, 8
(100%) patients had acute hepatitis, 4 (50%) patients had hepatic
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encephalopathy, 1 (12.5 %) patient had myocarditis, 2 (25%) patients had
AKI (Acute Kidney Injury), and 1 (12.5%) patient had ARDS (Adult
Respiratory Distress Syndrome).
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Figure - 24 Complications of Yellow phosphorus poisoning
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OUTCOME OF THE PATIENTS
Table - 26
Rodenticide
type
OUTCOME
TotalRecovered
Without
Complication
Recovered
With
Complication
Died
N % N % N % N %
Zinc
Phosphide 153 90.5 13 7.7 3 1.8 169 100
Bromadiolone 49 41.2 70 58.8 0 0 119 100
Brodifacoum 2 28.6 5 71.4 0 0 7 100
Yellow
Phosphorus 0 0 4 50 4 50 8 100
Total 204 67.3 92 30.4 7 2.3 303 100
Out of 169 patients who consumed zinc phosphide 153 (90.5%)
patients recovered without complication, 13 (7.7%) patients recovered
with complication, and 3 (1.8%) patients died.
Recovered
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Recovered With
Complication
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Figure - 25 Outcome of Zinc phosphide poisoning
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Out of 119 patients who consumed bromadiolone, 49 (41.2%)
patients recovered without complication, 70 (58.8%) patients recovered
with complication, and none of the patients died.
Out of 7 patients who consumed brodifacoum, 2 (28.6%) patients
recovered without complication, 5 (71.4%) patients recovered with
complication, and none of the patients died.
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70
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Figure - 26 Outcome of Bromadiolone poisoning
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Figure - 27 Outcome of Brodifacoum poisoning
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Out of 8 patients who consumed yellow phosphorus, 4 (50%)
patients recovered with complication, 4 (50%) patients died. 96.4% (163)
and none of the patients recovered without complication.
Out of the total 303 patients studied phosphide 204 (67.3%)
patients recovered without complication, 92 (30.4%) patients recovered
with complication, and 7 (2.3%) patients died.
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Figure - 28 Outcome of Yellow phosphorus poisoning
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Figure - 29 Total outcome of all the patients
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COMPLICATIONS
Table - 27
Complication
Zinc
phosphide Bromadiolone Brodifacoum
Yellow
Phosphorus Total
N  % N % N % N %  N  %
? INR without
haemorrhage 4 5.2 65 84.4 5 6.5 3 3.9 77 100
? INR with
haemorrhage 2 16.6 5 41.7 0 0 5 41.7 12 100
Acute hepatitis 5 38.5 0 0 0 0 8 61.5 13 100
Hepatic
encephalopathy 2 33.3 0 0 0 0 4 66.7 6 100
Myocarditis 0 0 0 0 0 0 1 100 1 100
Arrhythmia 1 100 0 0 0 0 0 0 1 100
AKI 0 0 0 0 0 0 2 100 2 100
Hypoglycaemia 9 100 0 0 0 0 0 0 9 100
ARDS 0 0 0 0 0 0 1 100 1 100
Total 23 18.8 70 57.4 5 4.1 24 19.7 122 100
Out of 77 patients who had increased INR without haemorrhage, 4
(5.2%) were due to Zinc Phosphide, 65 (84.4%) were due to
Bromadiolone, 5 (6.5%) were due to Brodifacoum, 3 (3.9%) were due to
Yellow Phosphorus.
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Out of 12 patients who had increased INR with haemorrhage, 4
(16.6%) were due to Zinc Phosphide, 5 (41.7%) were due to
Bromadiolone, 5 (41.7%) were due to Yellow Phosphorus.
? Myocarditis occurred in 1 patient which was due to Yellow
Phosphorus.
? Arrhythmia occurred in 1 patient which was due to Zinc phosphide.
? ARDS occurred in 1 patient which was due to Yellow Phosphorus.
? Hypoglycaemia occurred in 9 patients which were due to Zinc
phosphide.
? Acute Kidney Injury (AKI) occurred in 2 patients which were due
to Yellow Phosphorus.
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Out of 13 patients who had Acute Hepatitis, 5 (38.5%) were due to
Zinc Phosphide, 8 (61.5%) were due to Yellow Phosphorus.
Out of 6 patients who had increased Hepatic encephalopathy, 2
(33.3%) were due to Zinc Phosphide, 4 (66.7%) were due to Yellow
Phosphorus.
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Figure - 31 Acute hepatitis
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Figure - 32 Hepatic encephalopathy
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COMPARISION OF TIME DELAY IN PRESENTATION TO
HOSPITAL AND THEIR OUTCOME
Table - 28
Duration
Time delay to present to hospital in hours
Total
0 - 2 hours 2 – 6 hrs 6 – 12 hrs 12 – 24hrs > 24 hrs
N % N % N % N % N % N %
Recovered
Without
Complication
66 32.3 121 59.3 15 7.3 2 1 0 0 204 100
Recovered
With
Complication
42 45.6 41 44.5 4 4.3 1 1 4 4.3 92 100
Died 4 57.1 1 14.3 0 0 0 0 2 28.6 7 100
Total 112 37 163 53.8 19 6.2 3  1 6 2 303 100
Out of the 204 patients who recovered without any complications,
66 (32.3%) patients presented to hospital within 2 hours of rodenticide
ingestion, 121 (59.3%)  patients presented at 2 – 6 hours, 15 (7.3%)
patients presented at 6 – 12 hours, 2 (1%) patients presented at 12 – 24
hours, and none of the patients presented later than 24 hours after
ingestion.
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Figure - 33 Presentation - Time delay in patients who
Recovered Without Complication
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Out of the 92 patients who recovered with some complications, 42
(45.6%) patients presented to hospital within 2 hours of rodenticide
ingestion, 41 (44.5%) patients presented at 2 – 6 hours, 4 (4.3%) patients
presented at 6 – 12 hours, 1 (1%) patient presented at 12 – 24 hours, and
4 (4.3%) patients presented later than 24 hours after ingestion
Out of the 7 patients who died, 4 (57.1%) patient presented within
2 hours of rodenticide ingestion, 1 (14.3%) patient presented at 2 – 6
hours and 2 (28.6%) patients presented later than 24 hours after ingestion.
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Figure - 34 Presentation Time delay in  patients who
Recovered With Complications
0 - 2 hrs
(4)
2 – 6 hrs (1)
> 24 hrs (2)
Figure -35 Presentation - Time delay in patients who
died
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DISCUSSION
Rodenticide toxicity is a commonly encountered condition in an
emergency room setting. Most of the rodenticide poisoned patients
recover well. Only a few patients develop significant toxic effects and
even die. This varied clinical presentation depends on the type and
quantity of the rodenticide consumed and particularly their make
(whether locally prepared or a branded one). Instead of active ingredients,
most of the locally made preparations contain a large amount of inert
substances.
This  study  analyses  the  clinical  presentation  and  outcome  of
various types of rodenticide toxicity encountered in our centre. Patients
who were referred from other hospitals for the treatment of complications
due to rodenticide toxicity are also included in this study.
Most patients [300 (99%)] consumed rodenticide with a suicidal
intent.
80.2% (243) patients were below 30 years of age, signifying that
suicidal tendencies are common among this age group.
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Rodenticide consumption was found to be more common among
the married (59 %) as compared to unmarried (41 %). This may be
probably due to their marital stress.
275(90.8%) patients reached the hospital within 6 hours of
poisoning, 21(7.2%) patients reached between 6 – 24 hours, and 6 (2 %)
patients reached after 24 hours. Of the 6 (2%) patients who took more
than 24 hours to reach the hospital, 2 patients succumbed and 4 patients
recovered with complications. This clearly signifies that early and
appropriate medical care has a strong effect on the outcome of the
patients.
169 (55.8%) patients consumed zinc phosphide. Most of the
patients in this group consumed locally made preparation as it was very
cheap and easily available. 126(41.6%) patients consumed anticoagulant
rodenticide which was available in form of powder and cake. 8(2.6 %)
patients consumed yellow phosphorus which was available in form of a
paste.
84.6 % of patients with zinc phosphide poisoning presented with
vomiting which explains the highly emetic property of zinc phosphide
and the potassium antimony tartrate which is added with zinc phosphide
formulations to promote emesis.
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Most of the patients who consumed bromadiolone or brodifacoum
had no symptoms. Only a few patients had vomiting, abdominal pain at
presentation.
Patients with yellow phosphorus poisoning were admitted with
vomiting (75%), haemetemesis & malena (37.5%), icterus (75%). Of the
total 7 patients with yellow phosphorus poisoning, 3 patients were
referred from other hospitals for further management.
There were no demonstrable effects on the blood pressure and
pulse rate of the patients except for hypotension in 1 patient and
tachycardia in 7 patients.
3% of zinc phosphide poisoning and 100% of yellow phosphorus
poisoning had an elevated serum total bilirubin along with elevated
transaminases (ALT > AST) indicating significant hepatic involvement in
those patient.
Zinc phosphide poisoning
In Shyam P. Lohani et al study titled “An Epidemiological Study
on Acute Zinc Phosphide Poisoning in Nepal” conducted in Nepal from
1997 to 2002 analysed 178 patients on the clinical presentation and
outcome after zinc phosphide ingestion. The results revealed that 79%
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were asymptomatic, 18% had minor symptoms like abdominal pain,
vomiting, dizziness, 2% had major symptoms and 1% died [55].
Patial RK et al case study revealed two patients with acute zinc
phosphide poisoning developed severe hypoglycaemia and finally
succumbed [56].
A case report by Frangides CY and Pneumatikos IA reveals
persistent severe hypoglycaemia in patients with acute zinc phosphide
poisoning [57].
In our study 154 (91%) patients who consumed zinc phosphide
recovered without any complications. This may be due to highly emetic
effect of zinc and potassium antimony tartrate or due to low concentration
of the active ingredient present in the locally made preparations.
Out of 169 patients who consumed zinc phosphide 67 (39.6%)
patients had blood sugar of 55 – 90 mg / dl, and 9 (5.3%) patients had
blood sugar less than 55mg / dl. The blood sugar of all the patients
improved with administration of dextrose solution and the repeated blood
sugars until discharge of the patients were normal. This signifies that
there is a period of transient hypoglycaemia due to zinc phosphide
toxicity.
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Out of 9 (5.3%) patients had documented hypoglycaemia, 1 patient
died due to acute liver failure, and the remaining 8 patients recovered
with no other complications.
Of the 5 (2.95%) patients who developed acute hepatitis 2 patients
progressed to acute liver failure and succumbed.
 One patient developed ventricular tachycardia and died.
Anticoagulant Rodenticide poisoning
Ingels  M  et  al  study  on  unintentional  warfarin  poisoning  on  595
patients revealed no major coagulopathy and concluded that acute
unintentional superwarfarin ingestions of less than1 box can be managed
without gastric lavage or prophylactic vitamin K. and laboratory testing
for coagulopathy should be done for patients with clinically evident
bleeding abnormalities [58].
Chua JD and Friedenberg WR study on superwarfarin poisoning in
11 patients revealed no mortality. Coagulation abnormalities in all the
patients were successfully reverted with vitamin k1 therapy [59].
An 8 year consolidated data from the Annual report of the
American Association of Poison Control Centres, National Data
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Collection System (1988 - 1995) on superwarfarin poisoning by
LitovitzTLSchmitz revealed that there was a total of 79025 cases of
superwarfarin exposure or poisoning reported over a period of 8 years in
America. Out of which only 8 deaths were reported and only 67 patients
(0.08%) had major complications [60 - 67].
In our study 70 (59.7%) patients with bromadiolone poisoning and
5(71.4%) patients with brodifacoum poisoning had an increased INR after
48 hours. The remaining patients had no coagulation abnormalities or
other complications. Although the superwarfarin poisoning causes an
elevated INR, 49(41.2%) patients with bromadiolone poisoning and
2(28.6 %) patients with brodifacoum poisoning had normal INR in this
study. This could be explained by early gastrointestinal decontamination
or inadequate amounts ingested. There were no deaths in this group of
poisoning.
In our study most of the patients with superwarfarin poisoning did
not develop major complications.
Yellow phosphorus poisoning
Oscar Santos et al in their case series titled “Acute liver failure due
to white phosphorus ingestion” reported 3 patients with yellow
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phosphorus poisoning, out of which 2 patients died and 1 patient
recovered from acute fulminant hepatic failure [68].
S  Karanth  and  V  Nayyar  reported  2  patients  with  yellow
phosphorus poisoning with acute fulminant hepatitis. One of them
succumbed to death and other patient was discharged at 2 weeks
following signs of complete recovery [69].
Anupama Mauskar et al reported a case of accidental yellow
phosphorus poisoning in a 3 year old girl who initially was asymptomatic
but got admitted to hospital after 8 hours for vomiting, and later
developed acute fulminant liver failure and recovered after 3 weeks of
treatment [70].
Fernandez and Canizares in a case series of 15 patients have
reported a mortality rate of 27%, confirming that yellow phosphorus is
extremely lethal when ingested [40].
In our study all the patients who consumed yellow phosphorus
developed acute hepatitis. Out of which 4 (50%) patients progressed to
acute liver failure and succumbed. Other complications that were
observed in this study were myocarditis in 1 (12.5%) patient, AKI in 2
(25 %) patients, ARDS in 1 (12.5%) patient.
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All the patients with yellow phosphorus poisoning developed acute
hepatitis and they were treated with dextrose containing fluids. Hence
hypoglycaemia was not documented in this group. However there was
one patient with low blood sugar.
All the patients with yellow phosphorus poisoning in our study
were residents of salem and its suburban areas. This is probably due to
easy availability of yellow phosphorus paste which is commonly used as
rodenticide in paddy fields of salem. Those patients were referred to our
hospital for tertiary care from the primary care hospitals in and around
salem.
The time delay taken for the first medical contact is considered as
the poisoning to hospital presentation - time interval. 3 (75%) patients
who died due to yellow phosphorus poisoning consumed more than 10
grams of yellow phosphorus paste but presented to hospital within 2
hours of poisoning. Out of 4 patients who recovered with complications,
2 (50%) patients presented to hospital later than 24 hours of poisoning.
The above observation suggests the highly mortality in yellow
phosphorus poisoning is dependent on the amount of yellow phosphorus
ingested rather than the time delay at presentation.
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CONCLUSION
Rodenticide poisoning, though commonly remarked as ‘rat never
dies’; can be fatal to humans when the specific ingredient is consumed in
a lethal dose.
Although there are ample studies about individual types of
rodenticide, to our best of knowledge, we could not find any other study
in the literature that compares the various types. Having said that, we
must say the comparative study has yielded few striking facts.
? Zinc phosphide is the most prevalent poison in our study, but their
mortality and morbidity rate is very low
? Super warfarin poisoning, the second common rodenticide in
ourstudy, produced significant derangement in coagulation
parameters, but failed to manifest clinically. (In short, it is rather
benign)
? Yellow phosphorous, although leastcommon in our study, had a
significant impact on the patient’s outcome. The mortality rate is a
whopping 50% among the consumed.
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Rodenticide poisoning, though encountered every day, had so
many nuances and intricacies, which became apparent to us after
analysing their clinical profile.
Indeed, it is a very satisfying experience in a common poison!
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PROFOMA
Name
Age /sex:
Occupation:
Address with contact no:
IP No:
Date of admission:
Date of discharge/ death
Date and time of
consumption
  Amount of consumption
  Type of rodenticide
Vomiting Altered sensorium
Abdominal pain Muscle twitching
Haemetemesis Specific odour
Malena Breathlessness
Jaundice Others
Sensorium CVS
Icterus RS
Pedal edema P/A
Pallor CNS
BP PR
100
INVESTIGATIONS
TC DC ESR HB PCV MCV MCH MCHC PLT
Sugar Urea Cr Na K Hco3 Cl
TB DB SGOT SGPT SAP
Total
proteins
Albumin
PT APTT INR BT CT
Viral serology USG  abdomen
101
MASTER CHART - 1
TYPE AMT FORM Vom Abd pain Bleeding Icterus Others BP PR
1 37223 25 F M 1 BD 4 2 A A A A N N N N Rec / com + 1
2 37320 19 F UM 1 BD 3 2 A A A A N N N N Rec / com + 1
3 37346 30 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
4 37368 18 M UM 2 BD 1 1 A A A A N N N N Rec / com - 0
5 37429 23 M M 1 ZP 1 1 P A A A N N N N Rec / com - 0
6 37601 19 M UM 2 BD 2 1 A A A A N N N N Rec / com + 1
7 37793 13 M UM 3 BD 2 1 A A A A N N N N Rec / com - 0
8 37803 45 M M 1 BD 2 1 A A A A N N N N Rec / com + 1
9 37896 25 F M 2 BD 1 1 A A A A N N N N Rec / com + 1
10 38107 32 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
11 38153 30 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
12 38212 21 M UM 2 BD 1 1 A A A A N N N N Rec / com - 0
13 38383 17 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
14 38411 36 M M 1 BD 2 2 A A A A N N N N Rec / com + 1
15 38806 29 F M 1 BD 4 1 P P A A N N N N Rec / com + 1
16 38940 24 M M 2 BD 1 1 A A A A N N N N Rec / com + 1
17 39106 18 F UM 1 ZP 1 1 P A A A N N N N Rec / com - 0
18 40147 39 F M 1 BD 2 1 A A A A N N N N Rec / com + 1
19 40342 20 F UM 1 BD 2 1 A A A A N N N N Rec / com + 1
20 40589 20 M UM 1 BD 4 1 P A A A N N N N Rec / com + 1
21 40643 28 F M 2 BD 1 1 A A A A N N N N Rec / com - 0
22 40725 25 F M 2 ZP 1 1 P A A A N N N N Rec / com - 0
23 41216 23 M UM 1 BD 1 1 A A A A N N N N Rec / com - 0
24 41375 24 F M 2 ZP 1 1 P A A A N N N N Rec / com - 0
25 41480 28 M M 2 BD 1 1 A A A A N N N N Rec / com - 0
26 41531 21 M UM 2 ZP 2 1 P A A A N N N N Rec / com + 8
OUTCOME COMPLICATIONS.NO
SYSTEMI
C EXAM
RODENTENCIDE
IP.NO AGE SEX
MARITA
L
STATUS DURATION
Clinical feature at presentation VITALS
MASTER CHART - 1
27 41976 35 M M 2 ZP 1 1 A A A A N N N N Rec / com - 0
28 42422 28 M M 2 ZP 2 1 P P A A N N N N Rec / com + 8
29 42440 47 F M 1 BD 2 2 A A A A N N N N Rec / com + 1
30 42942 19 F UM 1 BD 3 1 P A A A N N N N Rec / com + 1
31 43393 20 M UM 1 BD 1 1 A A A A N N N N Rec / com + 1
32 43869 25 F UM 2 BD 3 2 P A A A N N N N Rec / com + 1
33 44014 52 F M 1 ZP 4 1 P A A A N N T N DIED 6
34 44085 66 M M 1 ZP 1 1 A A A A N N N N Rec / com + 0
35 49295 27 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
36 44309 18 F M 2 ZP 3 1 P P A A N N N N Rec / com - 0
37 44313 20 F UM 2 BD 2 1 A A A A N N N N Rec / com - 0
38 44500 20 M UM 1 BD 2 1 A A A A N N N N Rec / com + 1
39 44653 23 M M 1 ZP 2 2 P A A A N N N N Rec / com + 1
40 45029 21 M UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
41 45686 21 M UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
42 45692 17 F UM 2 BD 1 1 A A A A N N N N Rec / com - 0
43 45803 34 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
44 45848 27 F M 2 ZP 1 2 A A A A N N N N Rec / com - 0
45 45880 43 M M 4 BD 4 1 A A A A N N N N Rec / com + 1
46 46014 29 M M 2 ZP 3 1 P A A A N N N N Rec / com + 8
47 46294 60 M M 2 ZP 4 1 P A A A N N N N Rec / com + 8
48 46452 16 M UM 2 ZP 1 1 A A A A N N N N Rec / com - 0
49 46572 24 F M 1 ZP 3 1 P A A A N N N N Rec / com - 0
50 46574 22 F UM 3 ZP 3 1 P A A A N N N N Rec / com - 0
51 698 24 M M 2 BD 2 1 A A A A N N N N Rec / com + 1
52 736 42 M M 2 BD 3 2 P A A A N N N N Rec / com + 1
53 856 15 F UM 1 ZP 1 1 A P A A N N N N Rec / com - 0
54 934 24 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
55 943 24 M M 2 ZP 3 1 P A A A N N N N Rec / com - 0
MASTER CHART - 1
56 1099 18 M UM 1 YP 4 3 P A P P N N T N DIED 2,3,4,7
57 1210 22 M UM 1 ZP 2 1 P A A A N N N N Rec / com + 8
58 1468 20 F UM 1 BD 1 2 A A A A N N N N Rec / com + 1
59 1545 18 F UM 2 BD 1 1 A A A A N N N N Rec / com + 1
60 1636 21 F UM 2 ZP 3 1 P P A A N N N N Rec / com - 0
61 2076 28 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
62 2340 18 F UM 2 BD 2 1 A A A A N N N N Rec / com - 0
63 2369 18 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
64 2693 31 M M 2 BD 4 2 P A A A N N N N Rec / com + 1
65 2730 21 M M 2 ZP 2 1 P P A A N N N N Rec / com - 0
66 3354 30 M M 1 BD 2 1 A A A A N N N N Rec / com - 0
67 3607 14 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
68 3628 19 M UM 2 BD 3 2 P A A A N N N N Rec / com + 1
69 3944 16 F UM 2 ZP 1 1 A P A A N N N N Rec / com - 0
70 4002 34 M M 5 YP 2 3 A A A P N N N N Rec / com + 2,3
71 4919 60 F M 1 ZP 3 1 P A A A N N N N Rec / com - 0
72 5212 17 F UM 2 ZP 2 1 P P A A N N N N Rec / com - 0
73 5347 25 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
74 5556 24 M M 2 BD 4 2 A A A A N N N N Rec / com + 2
75 5594 33 F M 1 ZP 2 1 P A A A N N N N Rec / com - 0
76 5670 22 M UM 1 ZP 2 1 P A A A N N N N Rec / com - 0
77 6172 26 F M 1 BF 2 1 P A A A N N N N Rec / com - 0
78 6375 28 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
79 6465 29 F M 1 BD 4 1 P P A A N N N N Rec / com + 1
80 6565 20 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
81 6870 24 F M 5 ZP 4 1 P A A A N N N N DIED 2,3,4
82 7624 32 M M 1 ZP 1 1 A A A A N N N N Rec / com - 0
83 8316 26 F M 2 ZP 1 1 P A A A N N N N Rec / com - 0
84 8678 26 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
MASTER CHART - 1
85 8710 23 F M 1 BD 1 1 A A A A N N N N Rec / com - 0
86 8784 20 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
87 8796 19 F UM 1 BD 1 1 A A A A N N N N Rec / com - 0
88 9103 24 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
89 9332 23 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
90 9582 30 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
91 9765 31 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
92 9992 26 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
93 10148 16 F UM 1 BD 3 1 P A A A N N N N Rec / com + 1
94 10538 27 F M 2 ZP 1 1 P A A A N N N N Rec / com - 0
95 11519 17 F UM 2 ZP 1 1 P P A A N N N N Rec / com - 0
96 11536 30 F M 2 BD 3 1 A A A A N N N N Rec / com + 1
97 11569 16 F UM 3 ZP 3 1 P P A A N N N N Rec / com - 0
98 11591 30 F M 2 ZP 1 1 P A A A N N N N Rec / com - 0
99 12791 23 M UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
100 14976 34 M M 1 BD 2 2 P P A A N N N N Rec / com - 0
101 15248 26 M M 1 ZP 1 1 P A A A N N N N Rec / com - 0
102 15336 32 F M 2 ZP 1 1 A A A A N N N N Rec / com - 0
103 15800 28 M M 2 BD 2 1 A A A A N N N N Rec / com - 0
104 16259 25 F M 1 YP 4 3 P P P P N N T N DIED 2,3,4,7
105 16366 39 F M 2 ZP 3 1 P A A A N N N N Rec / com - 0
106 16458 40 M M 2 ZP 1 1 A P A A N N N N Rec / com - 0
107 16468 36 M M 1 BD 4 1 P A A A N N N N Rec / com + 1
108 17217 44 M M 2 BD 3 1 P A A A N N N N Rec / com + 1
109 17323 26 M M 5 ZP 4 1 P P A P N N N N Rec / com + 1,3
110 17327 21 F UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
111 17400 17 M UM 2 ZP 1 1 A A A A N N N N Rec / com - 0
112 17654 25 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
113 17708 25 M M 1 BD 2 1 A A A A N N N N Rec / com + 1
MASTER CHART - 1
114 18137 35 M M 2 ZP 3 1 P A A A N N N N Rec / com - 0
115 18146 22 F UM 1 ZP 3 1 P A A A N N N N Rec / com - 0
116 18201 21 M UM 1 BD 3 1 A A A A N N N N Rec / com + 1
117 18444 17 F UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
118 18475 50 M M 1 BD 2 2 A A A A N N N N Rec / com - 0
119 18675 18 F UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
120 18707 16 F UM 1 ZP 2 1 P A A A N N N N Rec / com - 0
121 18809 21 F UM 2 ZP 2 1 P P A A N N N N Rec / com - 0
122 18980 19 M UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
123 19366 25 F M 3 BD 3 2 P P A A N N N N Rec / com + 1
124 19419 19 F UM 1 BD 3 1 P P A A N N N N Rec / com + 1
125 19578 29 M M 2 ZP 2 1 P A A A N N N N Rec / com - 0
126 19764 18 M UM 1 YP 4 3 P P P P 1 N T 1 DIED 2,3,4
127 21051 27 F M 2 BF 4 1 P P A A N N N N Rec / com + 1
128 21194 22 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
129 21203 20 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
130 21395 20 M UM 1 BF 2 1 P P A A N N N N Rec / com + 1
131 21407 24 M M 4 ZP 2 1 P A A A N N N N Rec / com - 0
132 21793 33 F M 2 BD 2 1 A A A A N N N N Rec / com - 0
133 22119 34 F M 2 BD 1 2 A A A A N N N N Rec / com - 0
134 22325 18 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
135 22425 25 F M 4 ZP 1 1 P A A A N N N N Rec / com - 0
136 22503 35 F M 1 ZP 1 1 P P A A N N N N Rec / com - 0
137 22493 22 F UM 3 BD 4 2 A A A A N N N N Rec / com + 1
138 22524 20 M UM 1 BD 3 2 P P A A N N N N Rec / com - 0
139 22543 23 M UM 3 BD 1 1 A A A A N N N N Rec / com - 0
140 22865 17 F UM 2 ZP 3 1 P P A A N N N N Rec / com - 0
141 22862 17 F UM 1 BD 2 1 A A A A N N N N Rec / com - 0
142 24217 25 M M 1 BD 2 1 A A A A N N N N Rec / com - 0
MASTER CHART - 1
143 24674 24 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
144 24804 24 M M 5 ZP 4 1 P A A P N N N N Rec / com + 1,3
145 23145 40 M M 2 ZP 1 1 A A A A N N N N Rec / com - 0
146 23969 14 F UM 1 BD 3 1 P A A A N N N N Rec / com + 1
147 23999 18 M UM 2 ZP 3 1 P P A A N N N N Rec / com - 0
148 24692 19 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
149 24821 19 M UM 1 BD 3 2 A A A A N N N N Rec / com + 1
150 24924 31 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
151 24972 30 M M 2 ZP 1 1 A A A A N N N N Rec / com - 0
152 24994 37 M M 2 BD 3 1 P A A A N N N N Rec / com + 1
153 25395 21 F M 1 BD 1 1 A A A A N N N N Rec / com - 0
154 25406 18 M UM 2 BD 4 1 A A A A N N N N Rec / com + 1
155 25436 19 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
156 25694 19 M UM 1 ZP 1 1 P P A A N N N N Rec / com - 0
157 25737 32 M UM 1 BD 3 2 P A A A N N N N Rec / com + 1
158 25740 24 M UM 3 ZP 2 1 P A A A N N N N Rec / com - 0
159 25914 17 M UM 2 BD 3 2 P A A A N N N N Rec / com + 1
160 25917 28 M M 1 BD 3 1 P A A A N N N N Rec / com + 1
161 26111 20 F UM 2 ZP 1 1 A P A A N N N N Rec / com - 0
162 26765 21 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
163 26401 32 M M 1 ZP 4 1 P A A A N N N N Rec / com - 0
164 26463 21 M M 1 BD 1 1 P A A A N N N N Rec / com - 0
165 26523 21 M M 1 BD 1 2 A A A A N N N N Rec / com - 0
166 26574 19 F M 2 ZP 3 1 P A A A N N N N Rec / com - 0
167 26985 15 F UM 2 BD 4 1 P P A A N N N N Rec / com + 1
168 27066 23 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
169 27474 16 F UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
170 27481 24 M UM 2 ZP 4 1 P P A A N N N N Rec / com - 0
171 27617 15 F UM 2 BD 1 1 A A A A N N N N Rec / com - 0
MASTER CHART - 1
172 28249 16 M UM 2 BD 1 1 A A A A N N N N Rec / com - 0
173 28359 25 M M 2 ZP 4 1 P A A A N N N N Rec / com + 8
174 28550 29 M M 1 YP 2 3 P P A A N N N N Rec / com + 1,3
175 28873 22 F UM 2 BD 3 1 A A A A N N N N Rec / com + 1
176 28970 20 F M 1 ZP 3 1 P A A A N N N N Rec / com - 0
177 29168 18 F M 1 BD 3 1 P P A A N N N N Rec / com + 1
178 29321 35 F M 3 BD 4 1 A A A A N N N N Rec / com + 1
179 29685 20 F UM 1 ZP 2 1 P A A A N N N N Rec / com - 0
180 29801 21 F M 2 BD 3 2 A A A A N N N N Rec / com + 1
181 29947 13 F UM 1 ZP 1 1 A A A A N N N N Rec / com - 0
182 29975 23 M M 1 ZP 1 1 P A A A N N N N Rec / com - 0
183 30161 20 M UM 3 BD 2 1 A A A A N N N N Rec / com - 0
184 30307 30 M UM 2 ZP 2 1 P P A A N N N N Rec / com - 0
185 30352 29 F M 2 BD 3 2 A A A A N N N N Rec / com + 1
186 30367 31 M M 2 ZP 2 1 P A A A N N N N Rec / com - 0
187 30501 24 F M 2 BD 1 1 A A A A N N N N Rec / com - 0
188 30514 43 M M 3 ZP 1 1 A P A A N N N N Rec / com - 0
189 30681 37 M M 2 ZP 2 1 P A A A N N N N Rec / com - 0
190 30760 23 F M 3 BD 2 1 A A A A N N N N Rec / com - 0
191 31134 26 F M 3 ZP 4 1 P A A A N N N N Rec / com + 1,3
192 31423 21 F M 1 BD 1 1 A A A A N N N N Rec / com - 0
193 31447 30 F M 2 ZP 1 1 A A A A N N N N Rec / com - 0
194 31596 30 M M 3 BD 1 1 A A A A N N N N Rec / com - 0
195 31875 25 M M 1 ZP 1 1 P A A A N N N N Rec / com - 0
196 32348 20 M UM 2 ZP 4 1 P P A A N N N N Rec / com - 0
197 32568 22 M UM 2 BD 3 2 A A A A N N N N Rec / com + 1
198 32644 23 M UM 3 ZP 3 1 P A A A N N N N Rec / com - 0
199 32829 17 F UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
200 32906 17 F UM 2 BD 1 1 A P A A N N N N Rec / com - 0
MASTER CHART - 1
201 32925 25 F M 3 BD 1 1 A A A A N N N N Rec / com - 0
202 33055 22 F M 1 ZP 1 1 P A A A N N N N Rec / com - 0
203 33318 27 F M 2 BD 3 1 A A A A N N N N Rec / com + 1
204 33520 24 M UM 2 ZP 3 1 P P A A N N N N Rec / com - 0
205 33630 23 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
206 33764 28 F M 1 BD 2 2 A A A A N N N N Rec / com + 1
207 33846 53 M M 1 ZP 4 1 P A A A N N N N Rec / com - 0
208 34158 32 M M 1 ZP 4 1 P P A A N N N N Rec / com - 0
209 34196 27 M M 2 BD 2 1 P A A A N N N N Rec / com - 0
210 34486 29 M M 2 BD 3 2 A A A A N N N N Rec / com - 0
211 34596 34 F M 1 ZP 1 1 A P A A N N N N Rec / com - 0
212 34609 22 M UM 1 BD 3 1 P P A A N N N N Rec / com + 2
213 34614 18 F M 1 ZP 1 1 A A A A N N N N Rec / com - 0
214 34674 31 M M 1 ZP 2 1 P A A A N N N N Rec / com - 0
215 34761 36 M M 1 BD 4 2 A P A A N N N N Rec / com + 1
216 34897 20 M UM 2 ZP 4 1 P A A A N N N N Rec / com - 0
217 35020 25 M UM 2 ZP 3 1 P P A A N N N N Rec / com - 0
218 35080 25 M M 2 BD 4 2 P A A A N N N N Rec / com + 2
219 35118 37 M M 2 ZP 2 1 P P A A N N N N Rec / com - 0
220 35189 25 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
221 35340 32 M M 2 ZP 4 1 P A A A N N N N Rec / com - 0
222 35413 27 F M 2 BD 4 2 A A A A N N N N Rec / com + 1
223 35490 50 M M 2 BD 4 1 P P A A N N N N Rec / com + 1
224 35515 35 F M 2 BD 4 1 P A A A N N N N Rec / com + 1
225 35985 22 F M 2 ZP 1 1 A A A A N N N N Rec / com - 0
226 35995 28 M M 2 ZP 1 1 A P A A N N N N Rec / com - 0
227 36483 39 M M 2 BF 3 2 A A A A N N N N Rec / com + 1
228 36740 35 M M 2 BD 1 1 A A A A N N N N Rec / com - 0
229 36809 23 F M 3 BF 1 1 P A A A N N N N Rec / com - 0
MASTER CHART - 1
230 36980 20 M UM 1 YP 2 3 A P A A N N N N Rec / com + 1,3
231 37211 38 M M 2 ZP 2 1 P A A A N N N N Rec / com - 0
232 37337 24 F M 2 BD 1 1 A A A A N N N N Rec / com - 0
233 37367 26 M UM 2 ZP 2 1 P A A A N N N N Rec / com - 0
234 37706 21 M UM 2 ZP 4 1 P P A A N N N N Rec / com - 0
235 37737 20 M UM 2 BD 4 1 P A A A N N N N Rec / com + 1
236 37728 21 F UM 2 BD 3 1 P A A A N N N N Rec / com + 1
237 38047 26 F M 1 ZP 4 1 P P A A N N N N Rec / com - 0
238 38101 17 M UM 1 ZP 2 1 P A A A N N N N Rec / com - 0
239 38139 19 M UM 2 ZP 3 1 P A A A N N N N Rec / com - 0
240 38393 18 M UM 5 YP 3 3 P P A P 1,2 N T N Rec / com + 1,3
241 38462 19 F M 2 BD 1 1 A P A A N N N N Rec / com - 0
242 38672 27 M M 2 ZP 4 1 P A A A N N N N Rec / com - 0
243 38959 24 M UM 3 ZP 1 1 A A A A N N N N Rec / com - 0
244 38969 35 M M 2 BD 3 2 P A A A N N N N Rec / com + 1
245 39027 26 M UM 1 ZP 1 1 P P A A N N N N Rec / com - 0
246 39348 27 M M 1 ZP 3 1 P A A A N N N N Rec / com - 0
247 39420 27 F M 1 BD 2 2 A A A A N N N N Rec / com + 1
248 39419 17 M UM 2 ZP 2 1 P P A A N N N N Rec / com - 0
249 39810 20 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
250 39912 26 M M 1 BD 2 2 A A A A N N N N Rec / com + 2
251 40034 35 F M 2 BD 1 1 A A A A N N N N Rec / com - 0
252 40050 24 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
253 40352 22 F M 1 BD 3 2 A A A A N N N N Rec / com + 2
254 40486 25 F M 2 ZP 4 1 P A A A N N N N Rec / com - 0
255 40583 32 F M 1 ZP 3 1 P P A A N N N N Rec / com - 0
256 40857 24 F M 2 BD 1 1 A A A A N N N N Rec / com - 0
257 40879 29 F M 2 ZP 2 1 P P A A N N N N Rec / com - 0
258 41064 31 M M 1 ZP 4 1 P P A A N N N N Rec / com - 0
MASTER CHART - 1
259 41235 19 F M 1 BD 2 2 A A A A N N N N Rec / com + 1
260 41317 28 M M 1 ZP 1 1 A A A A N N N N Rec / com - 0
261 41377 18 M UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
262 41878 20 F M 3 BD 1 1 A A A A N N N N Rec / com - 0
263 42198 36 F M 2 ZP 3 1 P A A A N N N N Rec / com - 0
264 42305 15 F UM 1 BD 4 1 P P A A N N N N Rec / com + 1
265 42469 14 F UM 2 BD 3 1 P A A A N N N N Rec / com + 1
266 42472 23 M UM 1 ZP 2 1 P P A A N N N N Rec / com - 0
267 42496 22 M UM 2 BF 2 2 A A A A N N N N Rec / com + 1
268 42610 63 M M 1 ZP 3 1 P A A A N N N N Rec / com - 0
269 42809 23 M UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
270 42995 26 M M 1 ZP 4 1 P P A A N N N N Rec / com + 8
271 43003 17 F UM 1 BF 2 1 P P A A N N N N Rec / com + 1
272 43687 23 M UM 3 BD 1 1 A P A A N N N N Rec / com - 0
273 43120 27 M M 2 ZP 1 1 A A A A N N N N Rec / com - 0
274 43119 15 M UM 2 ZP 1 1 P A A A N N N N Rec / com - 0
275 43130 22 M UM 2 ZP 4 1 P A A A N N N N Rec / com - 0
276 43337 30 M M 2 BD 1 1 A P A A N N N N Rec / com - 0
277 43476 18 M UM 2 ZP 4 1 P A A A N N N N Rec / com - 0
278 43939 23 F M 1 BD 2 2 P A A A N N N N Rec / com - 0
279 44067 37 M M 2 ZP 1 1 P A A A N N N N Rec / com - 0
280 45057 16 F UM 1 BD 1 1 A A A A N N N N Rec / com - 0
281 49248 18 M UM 1 ZP 4 1 P A A A N N N N Rec / com - 0
282 49343 23 M UM 2 ZP 4 1 P P A P N L T N DIED 2,3,4,8
283 49426 18 F UM 2 ZP 4 1 P P A A N N N N Rec / com - 0
284 49447 84 M M 2 ZP 3 1 P A A A N N N N Rec / com - 0
285 49945 15 F UM 1 ZP 2 1 P A A A N N N N Rec / com - 0
286 50029 28 F M 1 ZP 2 1 P A A A N N N N Rec / com - 0
287 50078 20 M UM 5 YP 4 3 P P A P 2 N T 2 DIED 2,3,4,5,9
MASTER CHART - 1
288 50131 19 F M 2 ZP 2 1 P A A A N N N N Rec / com - 0
289 50149 26 M M 2 ZP 1 1 A P A A N N N N Rec / com - 0
290 50365 16 F UM 2 BD 2 1 A A A A N N N N Rec / com + 1
291 50552 26 M UM 2 BD 2 2 A A A A N N N N Rec / com - 0
292 50555 24 M M 2 ZP 4 1 P A A A N N N N Rec / com + 8
293 50970 22 M UM 2 BD 3 1 P A A A N N N N Rec / com + 1
294 51120 27 M M 1 ZP 1 1 A P A A N N N N Rec / com - 0
295 51131 27 M M 1 ZP 1 1 A A A A N N N N Rec / com - 0
296 51148 27 M M 2 BD 4 1 P A A A N N N N Rec / com + 1
297 51303 33 M M 1 BD 3 2 P A A A N N N N Rec / com + 1
298 52132 20 M UM 1 ZP 3 1 P A A A N N N N Rec / com - 0
299 52393 19 M UM 1 BD 2 1 A A A A N N N N Rec / com - 0
300 52475 28 M M 2 ZP 2 1 P P A A N N N N Rec / com - 0
301 52473 80 M M 1 BD 1 1 A A A A N N N N Rec / com - 0
302 52695 23 F M 1 BD 1 1 A A A A N N N N Rec / com - 0
303 53603 23 M UM 1 BD 3 2 P A A A N N N N Rec / com + 1
MASTER CHART - 2  (INVESTIGATIONS)
Sugar Ur Cr Electrolytes TB DB OT PT SAP TP AL PT APTT INR BT CT
1 37223 1 N N N N N N N N N N N I I 3 0 N Negative Normal
2 37320 1 N N N N N N N N N N N I I 3 0 N Negative Normal
3 37346 1 N N N N N N N N N N N N N 0 0 N Negative Normal
4 37368 1 N N N N N N N N N N N N N 0 0 N Negative Normal
5 37429 1 N N N N N N N N N N N N N 0 0 N Negative Normal
6 37601 1 N N N N N N N N N N N I N 2 0 N Negative Normal
7 37793 1 N N N N N N N N N N N N N 0 0 N Negative Normal
8 37803 1 N N N N N N N N N N N I N 2 0 N Negative Normal
9 37896 1 N N N N N N N N N N N I N 1 0 N Negative Normal
10 38107 2 N N N N N N N N N N N N N 0 0 N Negative Normal
11 38153 2 N N N N N N N N N N N N N 0 0 N Negative Normal
12 38212 1 N N N N N N N N N N N N N 0 0 N Negative Normal
13 38383 1 N N N N N N N N N N N N N 0 0 N Negative Normal
14 38411 1 N N N N N N N N N N A I I 2 0 N Negative Normal
15 38806 2 N N N N N N N N N N N I I 3 0 N Negative Normal
16 38940 1 N N N N N N N N N N N N N 0 0 N Negative Normal
17 39106 1 N N N N N N N N N N N N N 0 0 N Negative Normal
18 40147 1 N N N N N N N N N N A I I 3 0 N Negative Normal
19 40342 1 N N N N N N N N N N N I N 2 0 N Negative Normal
20 40589 2 N N N N N N N N N N N I I 4 0 N Negative Normal
21 40643 1 N N N N N N N N N N N N N 0 0 N Negative Normal
22 40725 1 N N N N N N N N N N N N N 0 0 N Negative Normal
23 41216 1 N N N N N N N N N N N I N 1 0 N Negative Normal
24 41375 2 N N N N N N N N N N A N N 0 0 N Negative Normal
25 41480 1 N N N N N N N N N N N N N 0 0 N Negative Normal
26 41531 3 N N N N N N N N N N N N N 0 0 N Negative Normal
VIRAL
SEROLOGY
USG
ABDOMENS.NO IP.NO
RFT LFT COAGULATION PROFILE
CBC
KEY TO MASTER CHART-1
COMPLICATIONS BLEEDING RODENTICIDE (TYPE)
1 ELEVATED INR WITHOUT HAEMORRHAGE A ABSENT ZP ZINC PHOSPHIDE
2 ELEVATED INR WITH  HAEMORRHAGE P PRESENT BD BROMODIALONE
3 ACUTE HEPATITIS BF BRODIFACOUM
4 HEPATIC ENCEPHALOPATHY ABD PAIN (ABDOMINAL PAIN) YP YELLOW PHOSPHORUS
5 MYOCARDITIS A ABSENT
6 ARRHYTHMIAS P PRESENT MARITAL STATUS
7 ACUTE KIDNEY INJURY UM UNMARRIED
8 HYPOGLYCEMIA OTHERS M MARRIED
9 ARDS 0 ABSENT
1 FEVER
OUTCOME 2 BREATHLESSNESS
Rec/com- RECOVERED WITHOUT COMPLICATION AMOUNT
Rec/com+ RECOVERED WITH COMPLICATION ICTERUS 1 < 2 GRAMS
DIED DIED A ABSENT 2 2 – 5 GRAMS
P PRESENT 3 5 – 10 GRAMS
4 > 10 GRAMS
BP (BLOOD PRESSURE) DURATION
N NORMAL 1 < 2 HOURS FORM
L HYPOTENSION (BP <90/60) 2 2 – 6 HOURS 1 POWDER
H HYPERTENSION(BP>140/90) 3 6 – 12 HOURS 2 BAR / CAKE
4 12 – 24 HOURS 3 PASTE
5 > 24 HOURS
PR (PULSE RATE) Vom (VOMITING) SYSTEMIC EXAMINATION
N NORMAL A ABSENT N NORMAL
B BRADYCARDIA (PR<60/MIN) P PRESENT 1 UNCONCIOUS
T TACHYCARDIA (PR> 100/MIN) 2 CREPITATIONS
MASTER CHART - 2  (INVESTIGATIONS)
27 41976 2 N N N N N N N N N N N N N 0 0 N Negative Normal
28 42422 3 N N N N N N N N N N N N N 0 0 N Negative Normal
29 42440 1 N N N N N N N N N N A I N 2 0 N Negative Normal
30 42942 2 N N N N N N N N N N N I I 3 0 N Negative Normal
31 43393 1 N N N N N N N N N N N I N 1 0 N Negative Normal
32 43869 1 N N N N N N N N N N N I I 4 0 N Negative Normal
33 44014 1 N N N N N N N N N N N N N 0 0 N Negative Normal
34 44085 2 N N N N N N N N N N N N N 0 0 N Negative Normal
35 49295 1 N N N N N N N N N N N N N 0 0 N Negative Normal
36 44309 2 N N N N N N N N N N N N N 0 0 N Negative Normal
37 44313 1 N N N N N N N N N N N I N 2 0 N Negative Normal
38 44500 2 N N N N N N N N N N N I N 1 0 N Negative Normal
39 44653 1 N N N N N N N N N N N N N 0 0 N Negative Normal
40 45029 1 N N N N N N N N N N N N N 0 0 N Negative Normal
41 45686 2 N N N N N N N N N N N N N 0 0 N Negative Normal
42 45692 1 N N N N N N N N N N A N N 0 0 N Negative Normal
43 45803 1 N N N N N N N N N N N N N 0 0 N Negative Normal
44 45848 1 N N N N N N N N N N A N N 0 0 N Negative Normal
45 45880 1 N N N N N N N N N N N I I 3 0 I Negative Normal
46 46014 3 N N N N N N N N N N N N N 0 0 N Negative Normal
47 46294 3 N N N N N N N N N N N N N 0 0 N Negative Normal
48 46452 1 N N N N N N N N N N N N N 0 0 N Negative Normal
49 46572 2 N N N N N N N N N N A N N 0 0 N Negative Normal
50 46574 2 N N N N N N N N N N N N N 0 0 N Negative Normal
51 698 1 N N N N N N N N N N N I I 2 0 N Negative Normal
52 736 1 N N N N N N N N N N N I I 4 0 N Negative Normal
53 856 1 N N N N N N N N N N N N N 0 0 N Negative Normal
54 934 2 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
55 943 2 N N N N N N N N N N N N N 0 0 N Negative Normal
56 1099 2 I I N I I I I I N N T I I 3 1 I Negative Normal
57 1210 3 N N N N N N N N N N N N N 0 0 N Negative Normal
58 1468 1 N N N N N N N N N N N I N 1 0 N Negative Normal
59 1545 2 N N N N N N N N N N N I N 1 0 N Negative Normal
60 1636 1 N N N N N N N N N N A N N 0 0 N Negative Normal
61 2076 1 N N N N N N N N N N A N N 0 0 N Negative Normal
62 2340 1 N N N N N N N N N N N N N 0 0 N Negative Normal
63 2369 1 N N N N N N N N N N N N N 0 0 N Negative Normal
64 2693 1 N N N N N N N N N N N I I 3 0 N Negative Normal
65 2730 1 N N N N N N N N N N N N N 0 0 N Negative Normal
66 3354 1 N N N N N N N N N N N N N 0 0 N Negative Normal
67 3607 1 N N N N N N N N N N N N N 0 0 N Negative Normal
68 3628 1 N N N N N N N N N N N I N 2 0 N Negative Normal
69 3944 2 N N N N N N N N N N N N N 0 0 N Negative Normal
70 4002 1 N N N I I I I I N N N I I 1 1 I Negative Normal
71 4919 2 N N N N N N N N N N N N N 0 0 N Negative Normal
72 5212 1 N N N N N N N N N N N N N 0 0 N Negative Normal
73 5347 2 N N N N N N N N N N N N N 0 0 N Negative Normal
74 5556 1 N N N N N N N N N N N I I 3 0 N Negative Normal
75 5594 1 N N N N N N N N N N N N N 0 0 N Negative Normal
76 5670 2 N N N N N N N N N N N N N 0 0 N Negative Normal
77 6172 1 N N N N N N N N N N N N N 0 0 N Negative Normal
78 6375 2 N N N N N N N N N N N N N 0 0 N Negative Normal
79 6465 1 N N N N N N N N N N N I N 2 0 N Negative Normal
80 6565 1 N N N N N N N N N N N N N 0 0 N Negative Normal
81 6870 1 N N N I I I I I N N T I I 4 1 I Negative Normal
82 7624 1 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
83 8316 1 N N N N N N N N N N N N N 0 0 N Negative Normal
84 8678 2 N N N N N N N N N N A N N 0 0 N Negative Normal
85 8710 2 N N N N N N N N N N N N N 0 0 N Negative Normal
86 8784 1 N N N N N N N N N N N N N 0 0 N Negative Normal
87 8796 1 N N N N N N N N N N N N N 0 0 N Negative Normal
88 9103 2 N N N N N N N N N N N N N 0 0 N Negative Normal
89 9332 2 N N N N N N N N N N N N N 0 0 N Negative Normal
90 9582 2 N N N N N N N N N N N N N 0 0 N Negative Normal
91 9765 2 N N N N N N N N N N N N N 0 0 N Negative Normal
92 9992 1 N N N N N N N N N N A N N 0 0 N Negative Normal
93 10148 1 N N N N N N N N N N A I N 2 0 N Negative Normal
94 10538 1 N N N N N N N N N N A N N 0 0 N Negative Normal
95 11519 1 N N N N N N N N N N N N N 0 0 N Negative Normal
96 11536 2 N N N N N N N N N N N N N 2 0 N Negative Normal
97 11569 2 N N N N N N N N N N N N N 0 0 N Negative Normal
98 11591 1 N N N N N N N N N N N N N 0 0 N Negative Normal
99 12791 1 N N N N N N N N N N N N N 0 0 N Negative Normal
100 14976 1 N N N N N N N N N N N N N 0 0 N Negative Normal
101 15248 1 N N N N N N N N N N N N N 0 0 N Negative Normal
102 15336 1 N N N N N N N N N N A N N 0 0 N Negative Normal
103 15800 1 N N N N N N N N N N N N N 0 0 N Negative Normal
104 16259 1 I I N I I I I I N N N I I 2 0 I Negative Normal
105 16366 2 N N N N N N N N N N N N N 0 0 N Negative Normal
106 16458 1 N N N N N N N N N N N N N 0 0 N Negative Normal
107 16468 1 N N N N N N N N N N N I N 2 0 N Negative Normal
108 17217 1 N N N N N N N N N N N I I 2 0 N Negative Normal
109 17323 2 N N N I I I I I N N N I N 1 0 N Negative Normal
110 17327 1 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
111 17400 1 N N N N N N N N N N N N N 0 0 N Negative Normal
112 17654 1 N N N N N N N N N N N N N 0 0 N Negative Normal
113 17708 1 N N N N N N N N N N N I I 2 0 N Negative Normal
114 18137 1 N N N N N N N N N N N N N 0 0 N Negative Normal
115 18146 2 N N N N N N N N N N N N N 0 0 N Negative Normal
116 18201 1 N N N N N N N N N N N I N 2 0 N Negative Normal
117 18444 1 N N N N N N N N N N N N N 0 0 N Negative Normal
118 18475 1 N N N N N N N N N N N N N 0 0 N Negative Normal
119 18675 1 N N N N N N N N N N A N N 0 0 N Negative Normal
120 18707 1 N N N N N N N N N N N N N 0 0 N Negative Normal
121 18809 2 N N N N N N N N N N N N N 0 0 N Negative Normal
122 18980 2 N N N N N N N N N N N N N 0 0 N Negative Normal
123 19366 1 N N N N N N N N N N N I I 3 0 N Negative Normal
124 19419 1 N N N N N N N N N N N I N 2 0 N Negative Normal
125 19578 1 N N N N N N N N N N N N N 0 0 N Negative Normal
126 19764 1 N N N I I I I I N N T I I 3 1 I Negative Normal
127 21051 1 N N N N N N N N N N N I N 2 0 N Negative Normal
128 21194 1 N N N N N N N N N N N N N 0 0 N Negative Normal
129 21203 1 N N N N N N N N N N N N N 0 0 N Negative Normal
130 21395 1 N N N N N N N N N N N I N 2 0 N Negative Normal
131 21407 1 N N N N N N N N N N N N N 0 0 N Negative Normal
132 21793 1 N N N N N N N N N N N N N 0 0 N Negative Normal
133 22119 1 N N N N N N N N N N N N N 0 0 N Negative Normal
134 22325 2 N N N N N N N N N N N N N 0 0 N Negative Normal
135 22425 1 N N N N N N N N N N N N N 0 0 N Negative Normal
136 22503 1 N N N N N N N N N N A N N 0 0 N Negative Normal
137 22493 1 N N N N N N N N N N N I I 2 0 N Negative Normal
138 22524 1 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
139 22543 1 N N N N N N N N N N N N N 0 0 N Negative Normal
140 22865 2 N N N N N N N N N N N N N 0 0 N Negative Normal
141 22862 1 N N N N N N N N N N N N N 0 0 N Negative Normal
142 24217 1 N N N N N N N N N N N N N 0 0 N Negative Normal
143 24674 1 N N N N N N N N N N N N N 0 0 N Negative Normal
144 24804 1 N N N I I I I I N N N I N 1 0 N Negative Normal
145 23145 1 N N N N N N N N N N N N N 0 0 N Negative Normal
146 23969 1 N N N N N N N N N N N I N 2 0 N Negative Normal
147 23999 2 N N N N N N N N N N N N N 0 0 N Negative Normal
148 24692 2 N N N N N N N N N N N N N 0 0 N Negative Normal
149 24821 1 N N N N N N N N N N N I I 3 0 N Negative Normal
150 24924 1 N N N N N N N N N N N N N 0 0 N Negative Normal
151 24972 1 N N N N N N N N N N N N N 0 0 N Negative Normal
152 24994 1 N N N N N N N N N N N I I 2 0 N Negative Normal
153 25395 1 N N N N N N N N N N N N N 0 0 N Negative Normal
154 25406 1 N N N N N N N N N N N I I 3 0 N Negative Normal
155 25436 2 N N N N N N N N N N N N N 0 0 N Negative Normal
156 25694 1 N N N N N N N N N N N N N 0 0 N Negative Normal
157 25737 1 N N N N N N N N N N N I N 2 0 N Negative Normal
158 25740 2 N N N N N N N N N N N N N 0 0 N Negative Normal
159 25914 1 N N N N N N N N N N N I I 2 0 N Negative Normal
160 25917 1 N N N N N N N N N N N I N 2 0 N Negative Normal
161 26111 1 N N N N N N N N N N N N N 0 0 N Negative Normal
162 26765 1 N N N N N N N N N N N N N 0 0 N Negative Normal
163 26401 2 N N N N N N N N N N N N N 0 0 N Negative Normal
164 26463 1 N N N N N N N N N N N N N 0 0 N Negative Normal
165 26523 1 N N N N N N N N N N N N N 0 0 N Negative Normal
166 26574 2 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
167 26985 1 N N N N N N N N N N N I I 4 0 N Negative Normal
168 27066 1 N N N N N N N N N N N N N 0 0 N Negative Normal
169 27474 1 N N N N N N N N N N N N N 0 0 N Negative Normal
170 27481 2 N N N N N N N N N N N N N 0 0 N Negative Normal
171 27617 1 N N N N N N N N N N N N N 0 0 N Negative Normal
172 28249 1 N N N N N N N N N N N N N 0 0 N Negative Normal
173 28359 3 N N N N N N N N N N N N N 0 0 N Negative Normal
174 28550 1 N N N I I I I I N N N I N 2 0 N Negative Normal
175 28873 1 N N N N N N N N N N N I N 2 0 N Negative Normal
176 28970 2 N N N N N N N N N N N N N 0 0 N Negative Normal
177 29168 1 N N N N N N N N N N N I N 2 0 N Negative Normal
178 29321 1 N N N N N N N N N N N I I 3 0 N Negative Normal
179 29685 2 N N N N N N N N N N N N N 0 0 N Negative Normal
180 29801 1 N N N N N N N N N N N I I 2 0 N Negative Normal
181 29947 1 N N N N N N N N N N N N N 0 0 N Negative Normal
182 29975 1 N N N N N N N N N N N N N 0 0 N Negative Normal
183 30161 1 N N N N N N N N N N N N N 0 0 N Negative Normal
184 30307 1 N N N N N N N N N N N N N 0 0 N Negative Normal
185 30352 2 N N N N N N N N N N N I N 2 0 N Negative Normal
186 30367 1 N N N N N N N N N N N N N 0 0 N Negative Normal
187 30501 1 N N N N N N N N N N N N N 0 0 N Negative Normal
188 30514 1 N N N N N N N N N N N N N 0 0 N Negative Normal
189 30681 2 N N N N N N N N N N N N N 0 0 N Negative Normal
190 30760 1 N N N N N N N N N N N N N 0 0 N Negative Normal
191 31134 2 N N N I I I I I N N N I N 1 0 N Negative Normal
192 31423 1 N N N N N N N N N N N N N 0 0 N Negative Normal
193 31447 1 N N N N N N N N N N N N N 0 0 N Negative Normal
194 31596 1 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
195 31875 2 N N N N N N N N N N N N N 0 0 N Negative Normal
196 32348 1 N N N N N N N N N N N N N 0 0 N Negative Normal
197 32568 1 N N N N N N N N N N N I I 3 0 N Negative Normal
198 32644 1 N N N N N N N N N N N N N 0 0 N Negative Normal
199 32829 2 N N N N N N N N N N N N N 0 0 N Negative Normal
200 32906 1 N N N N N N N N N N N N N 0 0 N Negative Normal
201 32925 1 N N N N N N N N N N N N N 0 0 N Negative Normal
202 33055 1 N N N N N N N N N N N N N 0 0 N Negative Normal
203 33318 1 N N N N N N N N N N A I I 3 0 N Negative Normal
204 33520 2 N N N N N N N N N N N N N 0 0 N Negative Normal
205 33630 1 N N N N N N N N N N N N N 0 0 N Negative Normal
206 33764 1 N N N N N N N N N N N N N 0 0 N Negative Normal
207 33846 2 N N N N N N N N N N N N N 0 0 N Negative Normal
208 34158 1 N N N N N N N N N N N N N 0 0 N Negative Normal
209 34196 1 N N N N N N N N N N N I N 2 0 N Negative Normal
210 34486 1 N N N N N N N N N N N I I 3 0 N Negative Normal
211 34596 1 N N N N N N N N N N N N N 0 0 N Negative Normal
212 34609 1 N N N N N N N N N N N I I 3 0 N Negative Normal
213 34614 1 N N N N N N N N N N N N N 0 0 N Negative Normal
214 34674 1 N N N N N N N N N N N N N 0 0 N Negative Normal
215 34761 1 N N N N N N N N N N N I I 3 0 N Negative Normal
216 34897 2 N N N N N N N N N N N N N 0 0 N Negative Normal
217 35020 2 N N N N N N N N N N N N N 0 0 N Negative Normal
218 35080 1 N N N N N N N N N N N I I 3 0 N Negative Normal
219 35118 2 N N N N N N N N N N N N N 0 0 N Negative Normal
220 35189 2 N N N N N N N N N N N N N 0 0 N Negative Normal
221 35340 2 N N N N N N N N N N N N N 0 0 N Negative Normal
222 35413 1 N N N N N N N N N N N I N 2 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
223 35490 1 N N N N N N N N N N N I I 4 0 N Negative Normal
224 35515 1 N N N N N N N N N N N I I 3 0 N Negative Normal
225 35985 1 N N N N N N N N N N N N N 0 0 N Negative Normal
226 35995 1 N N N N N N N N N N N N N 0 0 N Negative Normal
227 36483 1 N N N N N N N N N N N I I 3 0 N Negative Normal
228 36740 1 N N N N N N N N N N N N N 0 0 N Negative Normal
229 36809 1 N N N N N N N N N N A N N 0 0 N Negative Normal
230 36980 1 N N N I I I I I N N N I N 1 0 N Negative Normal
231 37211 2 N N N N N N N N N N N N N 0 0 N Negative Normal
232 37337 2 N N N N N N N N N N N N N 0 0 N Negative Normal
233 37367 2 N N N N N N N N N N N N N 0 0 N Negative Normal
234 37706 2 N N N N N N N N N N N N N 0 0 N Negative Normal
235 37737 1 N N N N N N N N N N N I N 2 0 N Negative Normal
236 37728 1 N N N N N N N N N N N I N 2 0 N Negative Normal
237 38047 1 N N N N N N N N N N N N N 0 0 N Negative Normal
238 38101 2 N N N N N N N N N N N N N 0 0 N Negative Normal
239 38139 2 N N N N N N N N N N N N N 0 0 N Negative Normal
240 38393 1 N N N I I I I I N N N I N 1 0 N Negative Normal
241 38462 1 N N N N N N N N N N N N N 0 0 N Negative Normal
242 38672 2 N N N N N N N N N N N N N 0 0 N Negative Normal
243 38959 2 N N N N N N N N N N N N N 0 0 N Negative Normal
244 38969 1 N N N N N N N N N N N I N 1 0 N Negative Normal
245 39027 1 N N N N N N N N N N N N N 0 0 N Negative Normal
246 39348 1 N N N N N N N N N N N N N 0 0 N Negative Normal
247 39420 1 N N N N N N N N N N N I I 2 0 N Negative Normal
248 39419 2 N N N N N N N N N N N N N 0 0 N Negative Normal
249 39810 1 N N N N N N N N N N N N N 0 0 N Negative Normal
250 39912 1 N N N N N N N N N N N I N 2 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
251 40034 1 N N N N N N N N N N N N N 0 0 N Negative Normal
252 40050 1 N N N N N N N N N N N N N 0 0 N Negative Normal
253 40352 1 N N N N N N N N N N N I I 3 0 N Negative Normal
254 40486 2 N N N N N N N N N N N N N 0 0 N Negative Normal
255 40583 1 N N N N N N N N N N N N N 0 0 N Negative Normal
256 40857 1 N N N N N N N N N N A N N 0 0 N Negative Normal
257 40879 1 N N N N N N N N N N N N N 0 0 N Negative Normal
258 41064 2 N N N N N N N N N N N N N 0 0 N Negative Normal
259 41235 1 N N N N N N N N N N N I N 2 0 N Negative Normal
260 41317 1 N N N N N N N N N N N N N 0 0 N Negative Normal
261 41377 1 N N N N N N N N N N N N N 0 0 N Negative Normal
262 41878 1 N N N N N N N N N N N N N 0 0 N Negative Normal
263 42198 2 N N N N N N N N N N N N N 0 0 N Negative Normal
264 42305 1 N N N N N N N N N N N I I 3 0 N Negative Normal
265 42469 1 N N N N N N N N N N N I I 3 0 N Negative Normal
266 42472 2 N N N N N N N N N N N N N 0 0 N Negative Normal
267 42496 1 N N N N N N N N N N N I N 2 0 N Negative Normal
268 42610 1 N N N N N N N N N N N N N 0 0 N Negative Normal
269 42809 1 N N N N N N N N N N N N N 0 0 N Negative Normal
270 42995 3 N N N N N N N N N N A N N 0 0 N Negative Normal
271 43003 2 N N N N N N N N N N N I N 2 0 N Negative Normal
272 43687 1 N N N N N N N N N N N N N 0 0 N Negative Normal
273 43120 1 N N N N N N N N N N N N N 0 0 N Negative Normal
274 43119 2 N N N N N N N N N N N N N 0 0 N Negative Normal
275 43130 1 N N N N N N N N N N N N N 0 0 N Negative Normal
276 43337 1 N N N N N N N N N N A N N 0 0 N Negative Normal
277 43476 1 N N N N N N N N N N N N N 0 0 N Negative Normal
278 43939 1 N N N N N N N N N N N N N 0 0 N Negative Normal
MASTER CHART - 2  (INVESTIGATIONS)
279 44067 1 N N N N N N N N N N N N N 0 0 N Negative Normal
280 45057 1 N N N N N N N N N N N N N 0 0 N Negative Normal
281 49248 1 N N N N N N N N N N N N N 0 0 N Negative Normal
282 49343 3 N N N I I I I I N N T I I 1 1 I Negative Normal
283 49426 1 N N N N N N N N N N N N N 0 0 N Negative Normal
284 49447 1 N N N N N N N N N N N N N 0 0 N Negative Normal
285 49945 1 N N N N N N N N N N N N N 0 0 N Negative Normal
286 50029 1 N N N N N N N N N N N N N 0 0 N Negative Normal
287 50078 1 N N N I I I I I N N N I I 1 0 N Negative Normal
288 50131 2 N N N N N N N N N N N N N 0 0 N Negative Normal
289 50149 2 N N N N N N N N N N N N N 0 0 N Negative Normal
290 50365 1 N N N N N N N N N N N I I 2 0 N Negative Normal
291 50552 1 N N N N N N N N N N N N N 0 0 N Negative Normal
292 50555 3 N N N N N N N N N N N N N 0 0 N Negative Normal
293 50970 1 N N N N N N N N N N N I I 3 0 N Negative Normal
294 51120 2 N N N N N N N N N N N N N 0 0 N Negative Normal
295 51131 2 N N N N N N N N N N N I I 4 0 N Negative Normal
296 51148 1 N N N N N N N N N N N I I 2 0 N Negative Normal
297 51303 1 N N N N N N N N N N N N N 0 0 N Negative Normal
298 52132 2 N N N N N N N N N N N N N 0 0 N Negative Normal
299 52393 1 N N N N N N N N N N N N N 0 0 N Negative Normal
300 52475 1 N N N N N N N N N N N N N 0 0 N Negative Normal
301 52473 1 N N N N N N N N N N N N N 0 0 N Negative Normal
302 52695 1 N N N N N N N N N N N N N 0 0 N Negative Normal
303 53603 1 N N N N N N N N N N N I I 4 0 N Negative Normal
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KEY TO MASTER CHART - 2
SUGAR mg/dl NORMAL INCREASED
1 >90 Ur Urea N I
2 55 – 90 Cr Creatinine N I
3 < 55 TB Total Bilirubin N I
DB Direct Bilirubin N I
INR OT SGOT N I
0 < 1.1 PT SGPT N I
1 1.1 – 2 SAP Alkaline phosphatase N I
2 2.1 – 3 TP Total Proteins N I
3 3.1 – 4 AL Albumin N I
4 >4 PT Prothrombin Time N I
APTT
Activated partial prothrombin
time N I
CBC BT Bleeding Time N I
N NORMAL CT Clotting Time N I
T THROMBOCYTOPENIA
A ANEMIC
